AU6234900A - Nucleic acid ligands to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met and to integrins - Google Patents

Description

WO 01/09159 PCT/USOO/20139 NUCLEIC ACID LIGANDS TO HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR (HGF/SF) OR ITS RECEPTOR C-MET AND TO INTEGRINS Field of the Invention 5 Described herein are methods for identifying and preparing high affinity nucleic acid ligands of hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The method utilized herein for identifying such nucleic acid ligands is called SELEX, an acronym for Systematic Evolution of Ligands by EXponential enrichment. The invention is also directed towards therapeutic and diagnostic reagents for diseases in which elevated 10 HGF and c-met activity are causative factors. Also described herein are methods for identifying nucleic acid ligands of integrins using the SELEX method. This aspect of the invention relates to integrin proteins, and methods and compositions for treating and diagnosing diseases involving integrins. 15 Background of the Invention Hepatocyte growth factor/scatter factor (abbreviated herein as HGF) is a potent cytokine which, through interaction with its receptor c-met, stimulates proliferation, morphogenesis, and migration of a wide variety of cell types, predominantly epithelial. HGF and c-met are involved in several cellular processes involved in tumorigenesis, 20 notably angiogenesis and motogenesis, the latter having been implicated in the migration of cells required for metastasis (reviewed in Jiang and Hiscox (1997) Histol Histopathol. 12:537-55; Tamagnone and Comoglio (1997) Cytokine Growth Factor Rev. 8:129-42; Jiang, et al. (1999) Crit Rev Oncol Hematol. 29:209-48). Interestingly, proteases that degrade the extracellular matrix also activate HGF, which in turn up-regulates urokinase 25 type plasminogen activator (uPA) and its receptor, resulting in an activating loop feeding the invasive and migratory processes required for metastatic cancer. HGF and the c-met receptor are expressed at abnormally high levels in a large variety of solid tumors. In addition to numerous demonstrations in vitro of the effects of HGF/c-met on the behavior of tumor cell lines, the levels of HGF and/or c-met have been 30 measured in human tumor tissues (reviewed in Jiang (1999) Crit Rev Oncol Hematol. 29:209-48). High levels of HGF and/or c-met have been.observed in liver, breast, WO 01/09159 PCT/USOO/20139 2 pancreas, lung, kidney, bladder, ovary, brain, prostate, gallbladder and myeloma tumors in addition to many others. For several of the cancer types listed above, the prognostic value of measuring HGF/c-met levels has been evaluated and found to be potentially useful for determining 5 the progression and severity of disease. The correlative data are strongest in the case of breast cancer (Ghoussoub, Dillon et al. (1998) Cancer. 82:1513-20; Toi, Taniguchi et al. (1998) Clin Cancer Res. 4:659-64), and non-small cell lung cancer (Siegfried, Weissfeld et al. (1997) Cancer Res. 57:433-9; Siegfried, Weissfeld et al. (1998) Ann Thorac Surg. 66:1915-8). 10 Elevated levels of HGF and c-met have also been observed in non-oncological settings, such as hypertension (Morishita, Aoki et al. (1997) J Atheroscler Thromb. 4:12-9; Nakamura, Moriguchi et al. (1998), Biochem Biophys Res Commun. 242:23 8-43), arteriosclerosis (Nishimura, Ushiyama et al. (1997) J Hypertens. 15:1137-42; Morishita, Nakamura et al. (1998) J Atheroscler Thromb. 4:128-34), myocardial infarction (Sato, 15 Yoshinouchi et al. (1998) J Cardiol. 32:77-82), and rheumatoid arthritis (Koch, Halloran et al. (1996) Arthritis Rheum. 39:1566-75), raising the possibility of additional therapeutic and diagnostic applications. The role of HGF/c-met in metastasis has been elucidated in mice using cell lines transformed with HGF/c-met (reviewed in Jeffers, Rong et al. (1996) J Mol Med. 74:505 20 13). In another metastasis model, human breast carcinoma cells expressing HGF/c-met were injected in the mouse mammary fat pad, resulting in eventual lung metastases in addition to the primary tumor (Meiners, Brinkmann et al. (1998) Oncogene. 16:9-20). Also, transgenic mice which overexpress HGF become tumor-laden at many loci (Takayama, LaRochelle et al. (1997) Proc. Natl. Acad. Sci. U.S.A. 94:701-6). 25 None of the data mentioned above provide proof of a direct causative role of HGF/c-met in human cancer, although the accumulated weight of the correlative data are convincing. However, a causal connection was established between germ-line c-met mutations, which constitutively activate its tyrosine kinase domain, and the occurrence of human papillary renal carcinoma (Schmidt, Duh et al. (1997) Nat Genet. 16:68-73). 30 Recent work on the relationship between inhibition of angiogenesis and the suppression or reversion of tumor progression shows great promise in the treatment of WO 01/09159 PCT/USOO/20139 3 cancer (Boehm, Folkman et al. (1997) Nature. 3 90:404-7). In this report, it was shown that the use of multiple angiogenesis inhibitors confers superior tumor suppression/regression compared to the effect of a single inhibitor. Angiogenesis is markedly stimulated by HGF, as well as vascular endothelial growth factor (VEGF) and 5 basic fibroblast growth factor (bFGF) (Rosen, Lamszus et al. (1997) Ciba Found Symp. 212:215-26). HGF and VEGF were recently reported to have an additive or synergistic effect on mitogenesis of human umbilical vein endothelial cells (HUVECs) (Van Belle, Witzenbichler et al. (1998) Circulation. 97:381-90). Similar combined effects are likely to contribute to angiogenesis and metastasis. 10 Human HGF protein is expressed as a single peptide chain of 728 amino acids (reviewed in Mizuno and Nakamura (1993) Exs. 65:1-29; Rubin, Bottaro et al. (1993) Biochim Biophys Acta. 1155:357-71; Jiang (1999) Crit Rev Oncol Hematol. 29:209-48). The amino-terminal 31 residue signal sequence of HGF is cleaved upon export, followed by proteolytic cleavage by uPA and/or other proteases. The mature protein is a 15 heterodimer consisting of a 463 residue a-subunit and a 234 residue p-subunit, linked via a single disulfide bond. HGF is homologous to plasminogen: its a-subunit contains an N terminal plasminogen-activator-peptide (PAP) followed by four kringle domains, and the p-subunit is a serine protease-like domain, inactive because it lacks critical catalytic amino acids. The recently solved crystal structure of an HGF fragment containing PAP and the 20 first kringle domain indicate that this region is responsible for heparin binding and dimerization (Chirgadze, Hepple et al. (1999) Nat Struct Biol. 6:72-9), in addition to receptor interaction. Human c-met protein is exported to the cell surface via a 23 amino acid signal sequence (reviewed in Comoglio (1993) Exs. 65:131-65; Rubin (1993) Biochim Biophys 25 Acta. 1155:357-71; Jiang (1999) Crit Rev Oncol Hematol. 29:209-48). The exported form of c-met is initially a pro-peptide which is proteolytically cleaved. The mature protein is a heterodimer consisting of an extracellular 50 kDa a-subunit bound by disulfide bonds to a 140 kDa p-subunit. In addition to its extracellular domain, the p-subunit has a presumed membrane-spanning sequence and a 435 amino acid intracellular domain containing a 30 typical tyrosine kinase.

WO 01/09159 PCT/USOO/20139 4 HGF is produced primarily by mesenchymal cells, while c-met is mainly expressed on cells of epithelial origin. HGF is very highly conserved at the amino acid level between species. This homology extends into the functional realm as observed in mitogenic stimulation of hepatocytes in culture by HGF across species, including human, rat, mouse, 5 pig and dog. This indicates that human HGF can be used cross-specifically in a variety of assays. Given the roles of HGF and c-met in disease, it would be desirable to have agents that bind to and inhibit the activity of these proteins. It would also be desirable to have agents that can quantitate the levels of HGF and c-met in individual in order to gather 10 diagnostic and prognostic information. The integrins are a class of heterodimeric integral membrane proteins, one or more of which are expressed by most cell types (Hynes (1992) Cell 69:11-25). Some 16 homologous at subunits and 8 homologous p subunits associate in various combinations to yield an extensive family of receptors. Each integrin heterodimer has a large extracellular 15 domain that mediates binding to specific ligands. These ligands may include plasma proteins, proteins expressed on the surface of adjacent cells, or components of the extracellular matrix. Several of the integrins show affinity for more than one ligand and many have overlapping specificities (Hynes (1992) Cell 69:11-25). Both the a and P subunits contribute to a small intracellular domain that contacts components of the actin 20 cytoskeleton, thus forming a physical link between proteins outside and inside the cell. Integrins play an important role in cellular adhesion and migration, and these properties are controlled by the cell, partly by modulation of integrin affinity for its ligands (so-called "inside-out" signaling). Conversely, the presence or absence of integrin ligation provides specific information about the cellular microenvironment, and in many 25 instances integrins serve as a conduit for signal transduction. Ligand binding by an integrin may promote its incorporation into focal adhesions, the assembly of cytoskeletal and intracellular signaling molecules into supra-molecular complexes, and the initiation of a cascade of downstream signaling events including protein phosphorylation, calcium release, and an increase in intracellular pH (reviewed by Schwartz et al. (1995) Ann. Rev. 30 Cell Dev. Biol. 11:549-99). Such "outside-in" signaling ties into pathways controlling cell proliferation, migration and apoptosis (Stromblad et al. (1996) J. Clin. Invest. 98:426-33; WO 01/09159 PCT/USOO/20139 5 Eliceiri et al. (1998) J. Cell. Biol. 140:1255-63). Integrins have been shown to play a role in such diverse physiological settings as embryonic development, wound healing, angiogenesis, clot formation, leukocyte extravasation, bone resorption and tumor metastasis. 5 The p3-containing integrins are among the best studied of the receptor superfamily. The pN subunit forms heterodimers with either c (ap3 3 ) or cr (alOpb). While these integrins show substantial overlap in ligand specificity, they play very different roles in normal physiology and in disease. aCp 3 is expressed by activated endothelial cells, smooth muscle cells, osteoclasts, 10 and, at a very low level, by platelets. It is also expressed by a variety of tumor cell types. The integrin binds to a number of plasma proteins or proteins of the extracellular matrix, many of which are associated with sites of inflammation or wound healing (Albelda (1991) Am. J. Resp. Cell Mol. Biol. 4:195-203). These include vitronectin, fibronectin, osteopontin, von Willebrand factor, thrombospondin, fibrinogen, and denatured collagen 15 Type I (Hynes (1992) Cell 69:11-25). Each of these proteins share a common sequence motif, arginine-glycine-aspartic acid (RGD), that forms the core of the integrin binding site. a(p 3 has been most intensely studied in the context of new blood vessel formation (angiogenesis) where it mediates the adhesion and migration of endothelial cells through 20 the extracellular matrix. Angiogenesis in adults is normally associated with the cyclical development of the corpus luteum and endometrium and with the formation of granulation tissue during wound repair. In the latter case, microvascular endothelial cells form vascular sprouts that penetrate into the temporary matrix within a wound. These cells transiently express Cp 3 and inhibition of the ligand binding function of the integrin 25 temporarily inhibits the formation of granulation tissue (Clark et al. (1996) Am. J. Pathol. 148:1407-21). In cytokine-stimulated or unstimulated angiogenesis on the chick chorioallantoic membrane, blockade of aCp 3 with a heterodimer-specific antibody prevents new vessel formation without affecting the pre-existing vasculature (Brooks et al. (1994) Science 264:569-71). Furthermore, the loss of adhesive contacts by endothelial cells 30 activated for angiogenesis induces a phenotype characteristic of apoptotic cells (Brooks et al. (1994) Cell 79:1157-64); that is, ligand binding by aAp3 appears to transmit a survival WO 01/09159 PCT/USOO/20139 6 signal to the cell. Thus, adhesion and/or signaling mediated by aop 3 is essential for the formation of new blood vessels. Solid tumors are unable to grow to significant size without an independent blood supply. It is currently hypothesized that the acquisition of an angiogenic phenotype is one 5 of the limiting steps in the growth of primary tumors and of tumors at secondary sites (Folkman (1995) Nat. Med. 1:27-31). In addition, while the vasculature that penetrates a tumor mass provides a source of oxygen and nutrients, it also serves as a conduit for metastatic cells to leave the primary tumor and migrate throughout the body. Thus, inhibition of angiogenesis may limit both the growth and metastasis of cancerous lesions. 1@ In experimental settings of tumor-induced angiogenesis, inhibition of ligand-binding by endothelial ap3 prevented the formation of new blood vessels (Brooks et al. (1994) Cell 79:1157-64; Brooks et al. (1995) J. Clin. Invest. 96:1815-22), and inhibitors of aop 3 were shown to reduce the growth of experimental tumors in vivo (Brooks et al. (1995) J. Clin. Invest. 96:1815-22; Carron et al. (1998) Canc. Res. 58:1930-5). 15 ap3 is not only expressed by the microvasculature within tumors, but in some cases, is also found on the surface of tumor cells themselves. In particular, expression of avp 3 integrin has been detected in tissue sections from tumors of melanocytic and astroglial origin (Albelda et al. (1990) Canc. Res. 50:6757-64; Gladson and Cheresh (1991) J. Clin. Invest. 88:1924-32), and the level of integrin expression has been correlated with the stage 20 or metastatic potential of the tumor (Albelda et al. (1990) Canc. Res. 50:6757-64; Gladson (1996) Am. J. Pathol. 148:1423-34; Hieken et al. (1996) J. Surg. Res. 63:169-73). Furthermore, melanoma cells grown in vitro in a three-dimensional matrix of denatured collagen undergo apoptosis upon avp 3 blockade. Data such as these have driven an interest in inhibitors of avp3 for the treatment of 25 cancer. At present, two such inhibitors are in or near clinical trial: Vitaxin is a chimeric Fab fragment derived from the a43-specific monoclonal antibody, LM609 (Wu et al. (1998) Proc. Nat. Acad. Sci. 95:6037-42). A phase I trial in late-stage cancer patients has been completed and no significant treatment-associated toxicities were observed (Gutheil et al. (1998) Am. Soc. Clin. Onc.). EMD121974 is a cyclic pentapeptide inhibitor of aop 3 . 30 A Phase I study of this compound in Kaposi's sarcoma, brain tumors and solid tumors is scheduled to begin in 1999.

WO 01/09159 PCT/USOO/20139 7 Angiogenesis (and ap 3 ) are implicated in the pathology of several other diseases, including psoriasis (Creamer et al. (1995) Am. J. Pathol. 147:1661-7), rheumatoid arthritis (Walsh et al. (1998) Am. J. Pathol. 152:691-702; Storgard et al. (1999) J. Clin. Invest. 103:47-54), endometriosis (Healy et al. (1998) Hum. Reprod. Update 4:736-40), and 5 several proliferative diseases of the eye (Casaroli Marano et al. (1995) Exp. Eye Res. 60:5 17; Friedlander et al. (1996) Proc. Nat. Acad. Sci. 93:9764-9; Hammes et al. (1996) Nat. Med. 2:529-33). Inhibition of integrin ligand binding in each of these contexts may provide significant therapeutic benefit. Atheromatous plaque and restenosis following angioplasty are pathologies 10 characterized by thickening of the intima, the innermost layer of the arterial wall. The proliferation and/or migration of smooth muscle cells into the neointima with concomitant deposition of fibrous extracellular proteins contributes to vessel wall thickening and subsequent vessel occlusion. Platelets may also contribute to the development of restenotic lesions through adhesion to endothelial cells and the release of growth factors 15 and cytokines that stimulate the underlying smooth muscle cell layer (Le Breton et al. (1996) J. Am. Coll. Cardiol. 28:1643-51). ap 3 integrin is expressed on arterial smooth muscle cells (Hoshiga et al. (1995) Circ. Res. 77:1129-35) and mediates their migration on vitronectin and osteopontin (Brown et al. (1994) Cardiovasc. Res. 28:1815-20; Jones et al. (1996) Proc. Nat. Acad. Sci. 93:2482-7; Liaw et al. (1995) J. Clin. Invest. 95:713-24; 20 Panda et al. (1997) Proc. Nat. Acad. Sci. 94:9308-13), two matrix proteins associated with atheroschlerotic tissues in vivo (Brown et al. (1994) Cardiovasc. Res. 28:1815-20; Giachelli et al. (1995) Ann. N. Y. Acad. Sci. 760:109-26; Panda et al. (1997) Proc. Nat. Acad. Sci. 94:9308-13). In addition, axp 3 expression on endothelial cells, and to a much lesser extent on platelets, is responsible for at least part of the adhesive interaction between 25 these cell types (Le Breton et al. (1996) J. Am. Coll. Cardiol. 28:1643-5 1; Gawaz et al. (1997) Circulation 96:1809-18). avp 3 blockade with RGD-containing peptides or a monoclonal antibody was found to limit neointimal hyperplasia in several animal models of restenosis following arterial injury (Choi et al. (1994) J. Vasc. Surg. 19:125-34; Srivatsa et al. (1997) Cardiovasc. Res. 36:408-28; Slepian et al. (1998) Circulation 30 97:1818-27; Coleman et al. (1999) Circ. Res. 84:1268-76). Furthermore, treatment of patients undergoing percutaneous coronary intervention with an anti-p3 antibody WO 01/09159 PCT/USOO/20139 8 (Reopro/abciximab/c7E3), which blocks both the platelet fibrinogen receptor, cmp3, and aAps, provided long term reduction in the rates of death or myocardial infarction and in the rate of reocclusion of the artery (Lefkovits et al. (1996) Am. J. Cardiol. 77:1045-5 1), an effect that may be mediated through inhibition of aop 3 ligation. The observation that ()p3 5 is expressed by microvascular smooth muscle cells after experimentally-induced focal cerebral ischemia (Okada et al. (1996) Am. J. Pathol. 149:37-44) suggests that this integrin may also play some role in the development of ischemia/reperfusion injury in stroke. Finally, xjp 3 mediates the attachment of osteoclasts to matrix proteins, particularly 10 osteopontin, on the surface of bone. Osteoclasts are responsible for the resorption of bone in normal physiology as well as in pathological conditions such as osteoporosis. A monoclonal antibody specific for Ca3 inhibited the binding and resorption of bone particles by osteoclasts in vitro (Ross et al. (1993) J. Biol. Chem. 268:9901-7). Furthermore, an RGD-containing protein, echistatin, was shown to block parathyroid 15 stimulated bone resorption in an animal model, as monitored by serum calcium levels (Fisher et al. (1993) Endocrin. 132:1411-3). Inhibitors of aLp3 3 integrin are thus considered of potential utility in treating debilitating bone loss such as occurs in osteoporosis. C.3 (also referred to as GPIIbIIIa) is the major integrin on the surface of platelets where it mediates the adhesion of activated platelets to the plasma protein fibrinogen 20 (Nachman and Leung (1982) J. Clin. Invest. 69:263-9; Shattil et al. (1985) J. Biol. Chem. 260:11107-14). During clot formation, fibrinogen dimers cross-link platelets to one another through the integrin receptor. amp3 also binds to several other plasma and cell matrix proteins, including von Willebrand factor, vitronectin, and fibronectin (Faull and Ginsberg (1996) J. Am. Soc. Nephrol. 7:1091-7). '25 Clot formation is a tightly regulated process that balances the need for rapid response to vascular injury, with the risk of aberrant occlusion of critical vessels. The Cp 3 heterodimer is constitutively expressed on the surface of resting platelets at approximately 80,000 copies per cell (Wagner et al. (1996) Blood 8_8:907-14); however, the affinity of the integrin for fibrinogen is very low on these cells. Activation of platelets 30 by ADP, epinephrine, collagen or thrombin leads to a dramatic enhancement in integrin ligand binding activity (Bennett and Vilaire (1979) J. Clin. Invest. 64:1393-401; WO 01/09159 PCT/USOO/20139 9 Marguerie et al. (1979) J. Biol. Chem. 254:5357-63), probably accomplished through a conformational change in the receptor (Shattil et al. (1985) J. Biol. Chem. 260:11107-14; O'Toole et al. (1990) Cell Reg. 1:883-93; Du et al. (1993) J. Biol. Chem. 268:23087-92). In this prototypic example of "inside-out" control of integrin function, cross-linking of 5 platelets through the aXIMp-fibrinogen interaction is confined to local sites of platelet activation. Inhibitors of alibp 3 ligand binding have been primarily explored in the context of cardiovascular disease (Chong (1998) Am. J. Health Syst. Pharm. 55:2363-86; Topol et al. (1999) Lancet 353 :227-31), but may have application in any of a number of indications 10 where thrombus formation is suspected or is likely. Three Cp3 3 inhibitors, Reopro, Integrilin and Aggrastat, have been approved for use in patients experiencing acute coronary syndrome and/or in patients who are undergoing percutaneous coronary intervention. Reopro (Centocor/Eli Lilly) is a humanized murine monoclonal antibody Fab fragment with specificity for the p 3 chain of a.p3. Integrilin (COR Therapeutics) is a 15 cyclic heptapeptide based on the integrin binding site of barbourin, an cLp]3 3 inhibitory protein derived from snake venom. Aggrastat (Merck & Co.) is a non-peptide small molecule antagonist of the integrin. Unlike the small molecule inhibitors, Reopro cross reacts with av3, a fact that may account for the greater reduction in long-term rates of death and non-fatal myocardial infarction associated with its use (see above). A 20 significant effort is underway to identify new inhibitors of the platelet integrin with characteristics not found in the cohort of approved drugs. Specifically, compounds with specificity for the active, ligand-binding conformation of (x 1 1 3 s may reduce the risk of bleeding complications associated with the existing anti-clotting therapies. Orally available compounds would be particularly useful for longer term therapy of patients at 25 risk for recurrent myocardial infarction or unstable angina. Given the role of integrins in the various disease states described above, it would be desirable to have high specificity inhibitors of particular integrins. The present invention provides such agents. The dogma for many years was that nucleic acids had primarily an informational 30 role. Through a method known as Systematic Evolution of Ligands by EXponential enrichment, termed the SELEX process, it has become clear that nucleic acids have three WO 01/09159 PCT/USOO/20139 10 dimensional structural diversity not unlike proteins. The SELEX process is a method for the in vitro evolution of nucleic acid molecules with highly specific binding to target molecules and is described in U.S. Patent Application Serial No. 07/536,428, filed June 11, 1990, entitled "Systematic Evolution of Ligands by EXponential Enrichment," now 5 abandoned, U.S. Patent No. 5,475,096, entitled "Nucleic Acid Ligands," and U.S. Patent No. 5,270,163 (see also WO 91/19813), entitled "Methods for Identifying Nucleic Acid Ligands," each of which is specifically incorporated herein by reference in its entirety. Each of these applications, collectively referred to herein as the SELEX Patent Applications, describes a fundamentally novel method for making a nucleic acid ligand to 10 any desired target molecule. The SELEX process provides a class of products which are referred to as nucleic acid ligands or aptamers, each having a unique sequence, and which has the property of binding specifically to a desired target compound or molecule. Each SELEX-identified nucleic acid ligand is a specific ligand of a given target compound or molecule. The 15 SELEX process is based on the unique insight that nucleic acids have sufficient capacity for forming a variety of two- and three-dimensional structures and sufficient chemical versatility available within their monomers to act as ligands (form specific binding pairs) with virtually any chemical compound, whether monomeric or polymeric. Molecules of any size or composition can serve as targets. The SELEX method applied to the 20 application of high affinity binding involves selection from a mixture of candidate oligonucleotides and step-wise iterations of binding, partitioning and amplification, using the same general selection scheme, to achieve virtually any desired criterion of binding affinity and selectivity. Starting from a mixture of nucleic acids, preferably comprising a segment of randomized sequence, the SELEX method includes steps of contacting the 25 mixture with the target under conditions favorable for binding, partitioning unbound nucleic acids from those nucleic acids which have bound specifically to target molecules, dissociating the nucleic acid-target complexes, amplifying the nucleic acids dissociated from the nucleic acid-target complexes to yield a ligand-enriched mixture of nucleic acids, then reiterating the steps of binding, partitioning, dissociating and amplifying through as 30 many cycles as desired to yield highly specific high affinity nucleic acid ligands to the target molecule.

WO 01/09159 PCT/USOO/20139 11 It has been recognized by the present inventors that the SELEX method demonstrates that nucleic acids as chemical compounds can form a wide array of shapes, sizes and configurations, and are capable of a far broader repertoire of binding and other functions than those displayed by nucleic acids in biological systems. 5 The basic SELEX method has been modified to achieve a number of specific objectives. For example, U.S. Patent Application Serial No. 07/960,093, filed October 14, 1992, now abandoned, and U.S. Patent No. 5,707,796, both entitled "Method for Selecting Nucleic Acids on the Basis of Structure," describe the use of the SELEX process in conjunction with gel electrophoresis to select nucleic acid molecules with specific 10 structural characteristics, such as bent DNA. U.S. Patent Application Serial No. 08/123,935, filed September 17, 1993, entitled "Photoselection of Nucleic Acid Ligands," now abandoned, U.S. Patent No. 5,763,177 and U.S. Patent No. 6,001,577, both entitled "Systematic Evolution of Ligands by Exponential Enrichment: Photoselection of Nucleic Acid Ligands and Solution SELEX," describe a SELEX based method for selecting 15 nucleic acid ligands containing photoreactive groups capable of binding and/or photocrosslinking to and/or photoinactivating a target molecule. U.S. Patent No. 5,580,737, entitled "High-Affinity Nucleic Acid Ligands That Discriminate Between Theophylline and Caffeine," describes a method for identifying highly specific nucleic acid ligands able to discriminate between closely related molecules, which can be non 20 peptidic, termed Counter-SELEX. U.S. Patent No. 5,567,588, entitled "Systematic Evolution of Ligands by EXponential Enrichment: Solution SELEX," describes a SELEX-based method which achieves highly efficient partitioning between oligonucleotides having high and low affinity for a target molecule. The SELEX method encompasses the identification of high-affinity nucleic acid 25 ligands containing modified nucleotides conferring improved characteristics on the ligand, such as improved in vivo stability or improved delivery characteristics. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions. SELEX process-identified nucleic acid ligands containing modified nucleotides are described in U.S. Patent No. 5,660,985, entitled "High Affinity Nucleic Acid Ligands 30 Containing Modified Nucleotides," that describes oligonucleotides containing nucleotide derivatives chemically modified at the 5- and 2'-positions of pyrimidines. U.S. Patent No.

WO 01/09159 PCT/USOO/20139 12 5,580,737, supra, describes highly specific nucleic acid ligands containing one or more nucleotides modified with 2'-amino (2'-NH 2), 2'-fluoro (2'-F), and/or 2'-methoxy (2' OMe). U.S. Patent Application Serial No. 08/264,029, filed June 22, 1994, entitled "Novel Method of Preparation of Known and Novel 2' Modified Nucleosides by 5 Intramolecular Nucleophilic Displacement," describes oligonucleotides containing various 2'-modified pyrimidines. The SELEX method encompasses combining selected oligonucleotides with other selected oligonucleotides and non-oligonucleotide functional units as described in U.S. Patent No. 5,637,459, entitled "Systematic Evolution of Ligands by EXponential 10 Enrichment: Chimeric SELEX," and U.S. Patent No. 5,683,867, entitled "Systematic Evolution of Ligands by EXponential Enrichment: Blended SELEX," respectively. These applications allow the combination of the broad array of shapes and other properties, and the efficient amplification and replication properties of oligonucleotides with the desirable properties of other molecules. 15 The SELEX method further encompasses combining selected nucleic acid ligands with lipophilic compounds or non-immunogenic, high molecular weight compounds in a diagnostic or therapeutic complex as described in U.S. Patent No. 6,011,020, entitled "Nucleic Acid Ligand Complexes." Each of the above described patent applications which describe modifications of the basic SELEX procedure are specifically incorporated herein 20 by reference in their entirety. It is an object of the present invention to obtain nucleic acid ligands to HGF and c met using the SELEX process. It is a further object of the invention to obtain nucleic acid ligands that act as inhibitors of HGF and c-met. 25 It is a further object of the invention to provide therapeutic and diagnostic agents for tumorigenic conditions in which HGF and c-met are implicated. It is yet a further object of the invention to use nucleic acid ligands to HGF and c met to diagnose and treat hypertension, arteriosclerosis, myocardial infarction, and rheumatoid arthritis.

WO 01/09159 PCT/USOO/20139 13 It is an even further object of the invention to use nucleic acid ligands to HGF singly or in combination with other nucleic acid ligands that inhibit VEGF and/or bFGF, and/or possibly other angiogenesis factors. It is also an object of the present invention to provide methods that can be used to 5 identify nucleic acid ligands that bind with high specificity and affinity to particular integrins. It is a further object of the present invention to obtain nucleic acid ligands to particular integrins that inhibit the ability of that integrin to bind its cognate ligand. It is a further object of the present invention to obtain integrin inhibiting 10 pharmaceutical compositions for controlling thrombosis, tumor angiogenesis, tumor cell migration, proliferative ocular diseases, rheumatoid arthritis, psoriasis, osteoporosis, and restenosis. It is yet a further object of the invention to obtain imaging agents for the non invasive detection of deep vein or arterial thrombi. 15 Summary of the Invention Methods are provided for generating nucleic acid ligands to HGF and c-met. The methods use the SELEX process for ligand generation. The nucleic acid ligands to HGF and c-met provided by the invention are useful as therapeutic and diagnostic agents for a 20 number of diseases. Methods are also provided for generating nucleic acid ligands to integrins, particularly to the p3 integrins. The methods use the SELEX process for ligand generation. Particular embodiments describe the isolation of nucleic acid ligand inhibitors of both axP 3 and ampJ. The nucleic acid ligand inhibitors are derived from a library of 2'-fluoro 25 pyrimidine RNA sequences and were selected for high affinity binding to ajp 3 . One of the modified nucleic acid ligands is shown to inhibit the binding of either vitronectin or fibrinogen to both of the purified integrins in vitro. This nucleic acid ligand binds to the surface of both resting and activated platelets with equivalent affinity and accumulates at the site of a preformed clot in an animal model of venous thrombosis.

WO 01/09159 PCT/USOO/20139 14 The nucleic acid ligands to integrins provided by the invention are useful as therapeutic agents for a number of diseases including thrombosis and cancer. The nucleic acid ligands of the instant invention are also useful as diagnostic agents for thrombosis. 5 Brief Description of the Drawings Figure 1 illustrates the template and primer oligonucleotides used in the 2'-F pyrimidine RNA SELEX experiments. The 5' fixed region of the template and primers contains a T7 promoter to facilitate transcription of RNA by T7 RNA polymerase. Figure 2 illustrates RNaseH cleavage primers used in hybridization truncate SELEX. 10 Bases depicted in bold-type are 2'-Ome modified and bases underlined are deoxyribonucleosides. The random region is designated as "N". Upon treatment with RNaseH, the fixed regions are removed at the positions indicated by the carets. Note that the there are two possible cleavage sites at the 5'-end of the fixed region, resulting in RNA which has one or two fixed G residues. 15 Figure 3 illustrates binding of SELEX pools to HGF. Figure 3A shows HGF SELEX 1 30N7 pools and Figure 3B shows HGF SELEX 2 30N8 pools. Figure 4 illustrates two methods of evaluating HGF SELEX 3 30N7 pool binding to HGF. In Figure 4A, heparin competes with RNA pools for binding to 2.7 nM HGF and Figure 4B illustrates conventional pool binding. 20 Figure 5 illustrates two methods of evaluating HGF SELEX 3 30N7 pool binding to HGF. Figure 5A shows that tRNA competes with RNA pools for binding to 2.7 nM HGF and Figure 5B shows conventional pool binding. Figure 6 illustrates inhibition of 10 ng/mL HGF stimulation of starved HUVECs by aptamers. Figure 6A shows a 1 s set of aptamers and Figure 6B illustrates a 2 nd set of 25 aptamers. Figure 7 illustrates truncates of aptamer 8-102 (SEQ ID NO:12). Figure 7A shows predicted two-dimensional structures of full-length and truncated sequences and Figure 7B shows binding of full-length and truncated aptamers to HGF. Figure 8 illustrates truncates of aptamer 8-17 (SEQ ID NO:68). Figure 8A .shows a 30 predicted two-dimensional structures of full-length and truncated sequences and Figure 8B shows binding of full-length and truncated aptamers to HGF.

WO 01/09159 PCT/USOO/20139 15 Figure 9 illustrates binding of HGF truncate SELEX pools. Figure 9A shows the HGF SELEX 4 30N7 series and Figure 9B shows the HGF SELEX 5 30N7 series. Figure 10 shows aptamer inhibition of 100 ng/mL HGF stimulation of 4MBr-5 cells. Figure 11 illustrates aptamer inhibition of 50 ng/mL HGF stimulation of 4MBr5 5 cells. Figure 11A shows the effect of PEGylation of 36mer and Figure 11B shows a comparison of PEGylated 36mer to best full-length inhibitor 8-17. Figure 12 shows aptamer inhibition of 50 ng/mL HGF stimulation of 4MBr-5 cells. Figure 13 shows HUVEC mitogenesis by 10 ng/mL HGF, 10 ng/mL VEGF, or both HGF and VEGF. 10 Figure 14 illustrates aptamer-mediated inhibition of HUVEC mitogenesis. Figure 14A shows stimulation by both HGF and VEGF inhibited by either HGF or VEGF aptamers or both. Figure 14B illustrates stimulation by HGF alone inhibited by either HGF or VEGF aptamer or both. Figure 14C illustrates stimulation by VEGF alone inhibited by either HGF or VEGF aptamer or both. 15 Figure 15 depicts ratios of selected to unselected partially 2'-OMe substituted purines in aptamer NX22354. Figure 16 illustrates 2'-OMe substituted derivatives of NX22354 binding to HGF (average of two experiments). Figure 17 illustrates binding of SELEX pools to c-met. Figure 17A shows c-Met 20 SELEX 40N7; Figure 17B shows c-Met SELEX 30N8; and Figure 17C shows both SELEXes: a, c pools, 40N7; b, d pools, 30N8. Figure 18 illustrates binding of c-met SELEX pools to c-met and KDR Ig fusion proteins. Figure 19 shows binding of c-met 40N7 cloned aptamers to c-met and KDR Ig 25 fusion proteins. Figure 19A shows clone 7c-1 and Figure 19B shows clone7c-3. Figure 20 illustrates the binding of affinity-enriched RNA pools to immobilized avP3. 5'-biotinylated RNA pools were incubated at varying concentrations in 96-well microtiter plates coated with integrin a(p 3 . Bound RNAs were detected via the biotin moiety by a chromogenic assay. Data are expressed in absorbance units at 405 nm as a 30 function of input RNA concentration.

WO 01/09159 PCT/USOO/20139 16 Figure 21 illustrates cross-reactivity of aptamer 17.16 (SEQ ID NO:249) to purified integrin cp 3 . 5'-biotinylated aptamer 17.16 was incubated at varying concentrations in microtiter wells coated with either integrin avp3 or c3. Bound RNA was detected via the biotin moiety using a chromogenic assay. Data are expressed as the per cent of the 5 maximum signal to normalize for differences in protein coating. Figure 22 illustrates cross-reactivity of aptamer 17.16 (SEQ ID NO:249) to purified integrin a4 5 . 5'-biotinylated aptamer 17.16 or a control RNA of similar length and base composition were incubated at varying concentrations in microtiter wells coated with either a3 or aps. Bound RNAs were detected via the biotin moiety by a chromogenic 10 assay. Data are expressed in absorbance units at 405 nm as a function of input RNA concentration. Figure 23 illustrates P3 aptamer inhibition of integrin ligand binding. Biotinylated fibrinogen or vitronectin were incubated in microtiter wells coated with either integrin a3 or CJp 3 in the presence or absence of varying concentrations of ligand binding 15 competitors. Competitors included aptamer 17.16 (SEQ ID NO:249), a control RNA of similar length and base composition, a cyclic RGD peptide (cRGD, see Materials and Methods), an aP 3 -specific monoclonal antibody (LM609), or unmodified fibrinogen or vitronectin. Bound ligands were detected via biotin using a chromogenic assay. Data are expressed in absorbance units at 405 nm as a function of input competitor concentration. 20 Figure 23A illustrates competition of vitronectin binding to immobilized aopA; Figure 23B illustrates competition of fibrinogen binding to immobilized CCap; and Figure 23C illustrates competition of fibrinogen binding to immobilized CI 3 p. An estimate of the maximum absorbance value was determined for each ligand/integrin pair in the absence of competitor. The baseline absorbance value was determined by adding 5 mM EDTA to the 25 incubation buffer. The maximum and minimum values so determined were (a) 0.914/0.113; (b) 1.042/0.122; and (c) 0.889/0.128. Figure 24 illustrates binding of aptamer 17.16 (SEQ ID NO:249) to activated or resting human platelets. 5'-fluorescein-conjugated aptamer 17.16 or a control RNA of similar length and base composition were incubated at various concentrations with resting 30 or thrombin-activated human platelets (10 6 /mL). Incubations were at room temperature in buffered saline containing divalent cations, 0.1% BSA and 0.01% sodium azide. Mean WO 01/09159 PCT/USOO/20139 17 fluorescence intensity of the sample was determined by flow cytometry, both before and after the addition of EDTA to 5 mM final concentration. The difference in fluorescence intensity between the two samples (the EDTA-sensitive signal) is shown as a function of the concentration of aptamer or control RNA. 5 Figure 25 illustrates biodistribution of [ 9 9 mTc]-aptamer 17.16 (SEQ ID NO:249) or control RNA in a rabbit venous clot model. A clot derived from human platelet-rich plasma was generated in situ by temporary isolation of the jugular vein of an anesthetized rabbit. After restoration of circulation over the clot, [ 9 9 mTc]-labeled aptamer or control RNA were injected into the bloodstream of the rabbit via the ipsilateral ear vein. After one 10 hour, the animal was sacrificed and tissues were weighed and counted in a gamma counter. Accumulation of radioactivity in various tissues is reported as the percentage of the injected dose per gram wet weight of tissue. Detailed Description of the Preferred Embodiments 15 The central method utilized herein for identifying nucleic acid ligands is called the SELEX process, an acronym for Systematic Evolution of Ligands by Exponential enrichment. As applied to identifying ligands to HGF and c-met the method comprises: a) contacting the candidate mixture of nucleic acids with HGF or c-met, or expressed domains or peptides corresponding to HGF or c-met; b) partitioning between members of 20 said candidate mixture on the basis of affinity to HGF or c-met; and c) amplifying the selected molecules to yield a mixture of nucleic acids enriched for nucleic acid sequences with a relatively higher affinity for binding to HGF or c-met. As applied to identifying integrins the method comprises: a) contacting the candidate mixture of nucleic acids with integrins, or expressed domains or peptides corresponding to integrins; b) partitioning 25 between members of said candidate mixture on the basis of affinity to integrins; and c) amplifying the selected molecules to yield a mixture of nucleic acids enriched for nucleic acid sequences with a relatively higher affinity for binding to integrins.

WO 01/09159 PCT/USOO/20139 18 Definitions Various terms are used herein to refer to aspects of the present invention. To aid in the clarification of the description of the components of this invention, the following definitions are provided. 5 As used herein, "nucleic acid ligand" is a non-naturally occurring nucleic acid having a desirable action on a target. Nucleic acid ligands are often referred to as "aptamers". The term aptamer is used interchangeably with nucleic acid ligand throughout this application. A desirable action includes, but is not limited to, binding of the target, catalytically changing the target, reacting with the target in a way which 10 modifies/alters the target or the functional activity of the target, covalently attaching to the target as in a suicide inhibitor, facilitating the reaction between the target and another molecule. In the preferred embodiment, the action is specific binding affinity for a target molecule, such target molecule being a three dimensional chemical structure other than a polynucleotide that binds to the nucleic acid ligand through a mechanism which 15 predominantly depends on Watson/Crick base pairing or triple helix binding, wherein the nucleic acid ligand is not a nucleic acid having the known physiological function of being bound by the target molecule. In the present invention, the targets are HGF, c-met and integrins or portions thereof. Nucleic acid ligands include nucleic acids that are identified from a candidate mixture of nucleic acids, said nucleic acid ligand being a ligand of a 20 given target, by the method comprising: a) contacting the candidate mixture with the target, wherein nucleic acids having an increased affinity to the target relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and c) amplifying the increased affinity nucleic acids to yield a ligand-enriched 25 mixture of nucleic acids. As used herein, "candidate mixture" is a mixture of nucleic acids of differing sequence from which to select a desired ligand. The source of a candidate mixture can be from naturally-occurring nucleic acids or fragments thereof, chemically synthesized nucleic acids, enzymatically synthesized nucleic acids or nucleic acids made by a 30 combination of the foregoing techniques. In a preferred embodiment, each nucleic acid WO 01/09159 PCT/USOO/20139 19 has fixed sequences surrounding a randomized region to facilitate the amplification process. As used herein, "nucleic acid" means either DNA, RNA, single-stranded or double-stranded, and any chemical modifications thereof. Modifications include, but are 5 snot limited to, those which provide other chemical groups that incorporate additional charge, polarizability, hydrogen bonding, electrostatic interaction, and fluxionality to the nucleic acid ligand bases or to the nucleic acid ligand as a whole. Such modifications include, but are not limited to, 2'-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, 10 substitution of 4-thiouridine, substitution of 5-bromo or 5-iodo-uracil; backbone modifications, methylations, unusual base-pairing combinations such as the isobases isocytidine and isoguanidine and the like. Modifications can also include 3' and 5' modifications such as capping. "SELEX" methodology involves the combination of selection of nucleic acid 15 ligands that interact with a target in a desirable manner, for example binding to a protein, with amplification of those selected nucleic acids. Optional iterative cycling of the selection/amplification steps allows selection of one or a small number of nucleic acids which interact most strongly with the target from a pool which contains a very large number of nucleic acids. Cycling of the selection/amplification procedure is continued 20 until a selected goal is achieved. In the present invention, the SELEX methodology is employed to obtain nucleic acid ligands to HGF, c-met and integrins or portions thereof. The SELEX methodology is described in the SELEX Patent Applications. "SELEX target" or "target" means any compound or molecule of interest for which a ligand is desired. A target can be a protein, peptide, carbohydrate, polysaccharide, 25 glycoprotein, hormone, receptor, antigen, antibody, virus, substrate, metabolite, transition state analog, cofactor, inhibitor, drug, dye, nutrient, growth factor, etc. without limitation. In this application, the SELEX targets are HGF, c-met and integrins. In particular, the SELEX targets in this application include purified integrins, HGF and c-met, and fragments thereof, and short peptides or expressed protein domains comprising HGF or c 30 met. Also includes as targets are fusion proteins comprising portions of HGF or c-met and other proteins.

WO 01/09159 PCT/USOO/20139 20 As used herein, "solid support" is defined as any surface to which molecules may be attached through either covalent or non-covalent bonds. This includes, but is not limited to, membranes, microtiter plates, magnetic beads, charged paper, nylon, Langmuir Bodgett films, functionalized glass, germanium, silicon, PTFE, polystyrene, gallium 5 arsenide, gold, and silver. Any other material known in the art that is capable of having functional groups such as amino, carboxyl, thiol or hydroxyl incorporated on its surface, is also contemplated. This includes surfaces with any topology, including, but not limited to, spherical surfaces and grooved surfaces. As used herein, "HGF" refers to hepatocyte growth factor/scatter factor. This 10 includes purified hepatocyte growth factor/scatter factor, fragments of hepatocyte growth factor/scatter factor, chemically synthesized fragments of hepatocyte growth factor/scatter factor, derivatives or mutated versions of hepatocyte growth factor/scatter factor, and fusion proteins comprising hepatocyte growth factor/scatter factor and another protein. "HGF" as used herein also includes hepatocyte growth factor/scatter factor isolated from 15 species other than humans. As used herein "c-met" refers to the receptor for HGF. This includes purified receptor, fragments of receptor, chemically synthesized fragments of receptor, derivatives or mutated versions of receptor, and fusion proteins comprising the receptor and another protein. "c-met" as used herein also includes the HGF receptor isolated from a species 20 other than humans. As used herein "integrin" refers to any integrin. This includes purified integrins, fragments of integrins, chemically synthesized fragments of integrins, derivatives or mutated versions of integrins, and fusion proteins comprising the integrin and another protein. "Integrins" as used herein also includes integrins isolated from a species other 25 than humans. Note that throughout this application, various references are cited. Every reference cited herein is specifically incorporated in its entirety. SELEX 30 In the preferred embodiment, the nucleic acid ligands of the present invention are derived from the SELEX methodology. The SELEX process is described in U.S. Patent WO 01/09159 PCT/USOO/20139 21 Application Serial No. 07/536,428, entitled "Systematic Evolution of Ligands by Exponential Enrichment," now abandoned, U.S. Patent No. 5,475,096, entitled "Nucleic Acid Ligands" and U.S. Patent No. 5,270,163 (see also WO 91/19813), entitled "Methods for Identifying Nucleic Acid Ligands." These applications, each specifically incorporated 5 herein by reference, are collectively called the SELEX Patent Applications. The SELEX process provides a class of products which are nucleic acid molecules, each having a unique sequence, and each of which has the property of binding specifically to a desired target compound or molecule. Target molecules are preferably proteins, but can also include among others carbohydrates, peptidoglycans and a variety of small 10 molecules. SELEX methodology can also be used to target biological structures, such as cell surfaces or viruses, through specific interaction with a molecule that is an integral part of that biological structure. In its most basic form, the SELEX process may be defined by the following series of steps: 15 1) A candidate mixture of nucleic acids of differing sequence is prepared. The candidate mixture generally includes regions of fixed sequences (i.e., each of the members of the candidate mixture contains the same sequences in the same location) and regions of randomized sequences. The fixed sequence regions are chosen either: a) to assist in the amplification steps described below; b) to mimic a sequence known to bind to the target; 20 or c) to enhance the concentration of a given structural arrangement of the nucleic acids in the candidate mixture. The randomized sequences can be totally randomized (i.e., the probability of finding a base at any position being one in four) or only partially randomized (e.g., the probability of finding a base at any location can be selected at any level between 0 and 100 percent). 25 2) The candidate mixture is contacted with the selected target under conditions favorable for binding between the target and members of the candidate mixture. Under these circumstances, the interaction between the target and the nucleic acids of the candidate mixture can be considered as forming nucleic acid-target pairs between the target and those nucleic acids having the strongest affinity for the target. 30 3) The nucleic acids with the highest affinity for the target are partitioned from those nucleic acids with lesser affinity to the target. Because only an extremely small WO 01/09159 PCT/USOO/20139 22 number of sequences (and possibly only one molecule of nucleic acid) corresponding to the highest affinity nucleic acids exist in the candidate mixture, it is generally desirable to set the partitioning criteria so that a significant amount of the nucleic acids in the candidate mixture (approximately 5-50%) are retained during partitioning. 5 4) Those nucleic acids selected during partitioning as having the relatively higher affinity for the target are then amplified to create a new candidate mixture that is enriched in nucleic acids having a relatively higher affinity for the target. 5) By repeating the partitioning and amplifying steps above, the newly formed candidate mixture contains fewer and fewer unique sequences, and the average degree of 10 affinity of the nucleic acids to the target will generally increase. Taken to its extreme, the SELEX process will yield a candidate mixture containing one or a small number of unique nucleic acids representing those nucleic acids from the original candidate mixture having the highest affinity to the target molecule. The basic SELEX method has been modified to achieve a number of specific 15 objectives. For example, U.S. Patent Application Serial No. 07/960,093, filed October 14, 1992, now abandoned, and U.S. Patent No. 5,707,796, both entitled "Method for Selecting Nucleic Acids on the Basis of Structure," describe the use of the SELEX process in conjunction with gel electrophoresis to select nucleic acid molecules with specific structural characteristics, such as bent DNA. U.S. Patent Application Serial No. 20 08/123,935, filed September 17, 1993, entitled "Photoselection of Nucleic Acid Ligands," now abandoned, U.S. Patent No. 5,763,177 and U.S. Patent No. 6,001,577, both entitled "Systematic Evolution of Ligands by Exponential Enrichment: Photoselection of Nucleic Acid Ligands and Solution SELEX" all describe a SELEX based method for selecting nucleic acid ligands containing photoreactive groups capable of binding and/or 25 photocrosslinking to and/or photoinactivating a target molecule. U.S. Patent No. 5,580,737, entitled "High-Affinity Nucleic Acid Ligands That Discriminate Between Theophylline and Caffeine," describes a method for identifying highly specific nucleic acid ligands able to discriminate between closely related molecules, termed Counter SELEX. U.S. Patent No. 5,567,588, entitled "Systematic Evolution of Ligands by 30 Exponential Enrichment: Solution SELEX," describes a SELEX-based method which achieves highly efficient partitioning between oligonucleotides having high and low WO 01/09159 PCT/USOO/20139 23 affinity for a target molecule. U.S. Patent No. 5,496,938, entitled "Nucleic Acid Ligands to HIV-RT and HIV-I Rev," describes methods for obtaining improved nucleic acid ligands after SELEX has been performed. U.S. Patent No. 5,705,337, entitled "Systematic Evolution of Ligands by Exponential Enrichment: Chemi-SELEX," describes methods for 5 covalently linking a ligand to its target. The SELEX method encompasses the identification of high-affinity nucleic acid ligands containing modified nucleotides conferring improved characteristics on the ligand, such as improved in vivo stability or improved delivery characteristics. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base 10 positions. SELEX-identified nucleic acid ligands containing modified nucleotides are described in U.S. Patent No. 5,660,985, entitled "High Affinity Nucleic Acid Ligands Containing Modified Nucleotides," that describes oligonucleotides containing nucleotide derivatives chemically modified at the 5- and 2'-positions of pyrimidines. U.S. Patent No. 5,637,459, supra, describes highly specific nucleic acid ligands containing one or more 15 nucleotides modified with 2'-amino (2'-NH 2 ), 2'-fluoro (2'-F), and/or 2'-0-methyl (2' OMe). U.S. Patent Application Serial No. 08/264,029, filed June 22, 1994, entitled "Novel Method of Preparation of Known and Novel 2' Modified Nucleosides by Intramolecular Nucleophilic Displacement," describes oligonucleotides containing various 2'-modified pyrimidines. 20 The SELEX method encompasses combining selected oligonucleotides with other selected oligonucleotides and non-oligonucleotide functional units as described in U.S. Patent No. 5,637,459, entitled "Systematic Evolution of Ligands by Exponential Enrichment: Chimeric SELEX," and U.S. Patent No. 5,683,867, entitled "Systematic Evolution of Ligands by Exponential Enrichment: Blended SELEX," respectively. These 25 applications allow the combination of the broad array of shapes and other properties, and the efficient amplification and replication properties, of oligonucleotides with the desirable properties of other molecules. In U.S. Patent No. 5,496,938, methods are described for obtaining improved nucleic acid ligands after the SELEX process has been performed. This patent, entitled 30 "Nucleic Acid Ligands to HIV-RT and HIV-1 Rev," is specifically incorporated herein by reference in its entirety.

WO 01/09159 PCT/USOO/20139 24 One potential problem encountered in the diagnostic use of nucleic acids is that oligonucleotides in their phosphodiester form may be quickly degraded in body fluids by intracellular and extracellular enzymes such as endonucleases and exonucleases before the desired effect is manifest. Certain chemical modifications of the nucleic acid ligand can 5 be made to increase the in vivo stability of the nucleic acid ligand or to enhance or to mediate the delivery of the nucleic acid ligand. See, e.g., U.S. Patent Application Serial No. 08/117,991, filed September 8 1993, now abandoned and U.S. Patent No. 5,660,985, both entitled "High Affinity Nucleic Acid Ligands Containing Modified Nucleotides," and the U.S. Patent Application Serial No. 09/362,578, filed July 28, 1999, entitled 10 "Transcription-free SELEX," each of which is specifically incorporated herein by reference. Modifications of the nucleic acid ligands contemplated in this invention include, but are not limited to, those which provide other chemical groups that incorporate additional charge, polarizability, hydrophobicity, hydrogen bonding, electrostatic interaction, and fluxionality to the nucleic acid ligand bases or to the nucleic acid ligand as 15 a whole. Such modifications include, but are not limited to, 2'-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5-iodo-uracil; backbone modifications, phosphorothioate or alkyl phosphate modifications, methylations, unusual base-pairing combinations such as the isobases isocytidine and 20 isoguanidine and the like. Modifications can also include 3' and 5' modifications such as capping. In preferred embodiments of the instant invention, the nucleic acid ligands are RNA molecules that are 2'-fluoro (2'-F) modified on the sugar moiety of pyrimidine residues. The modifications can be pre- or post-SELEX process modifications. Pre-SELEX 25 process modifications yield nucleic acid ligands with both specificity for their SELEX target and improved in vivo stability. Post-SELEX process modifications made to 2'-OH nucleic acid ligands can result in improved in vivo stability without adversely affecting the binding capacity of the nucleic acid ligand. Other modifications are known to one of ordinary skill in the art. Such modifications may be made post-SELEX process 30 (modification of previously identified unmodified ligands) or by incorporation into the SELEX process.

WO 01/09159 PCT/USOO/20139 25 In some embodiments, the nucleic acid ligands become covalently attached to their targets upon irradiation of the nucleic acid ligand with light having a selected wavelength. Methods for obtaining such nucleic acid ligands are detailed in U.S. Patent Application Serial No. 08/123,935, filed September 17, 1993, entitled "Photoselection of Nucleic Acid 5 Ligands," now abandoned, U.S. Patent No. 5,763,177 and U.S. Patent No. 6,001,577, both entitled "Systematic Evolution of Nucleic Acid Ligands by Exponential Enrichment: Photoselection of Nucleic Acid Ligands and Solution SELEX," each of which is specifically incorporated herein by reference in its entirety. The nucleic acid ligands of the invention are prepared through the SELEX 10 methodology that is outlined above and thoroughly enabled in the SELEX applications incorporated herein by reference in their entirety. Nucleic acid ligands to HGF and c-met The SELEX process can be performed using purified HGF or c-met, or fragments 15 thereof as a target. Alternatively, full-length HGF or c-met, or discrete domains of HGF or c-met, can be produced in a suitable expression system. Alternatively, the SELEX process can be performed using as a target a synthetic peptide that includes sequences found in HGF or c-met. Determination of the precise number of amino acids needed for the optimal nucleic acid ligand is routine experimentation for skilled artisans. 20 In preferred embodiments, the SELEX process is carried out using HGF or c-met attached to a solid support. A candidate mixture of single stranded RNA molecules is then contacted with the solid support. In especially preferred embodiments, the single stranded RNA molecules have a 2'-fluoro modification on C and U residues, rather than a 2'-OH group. After incubation for a predetermined time at a selected temperature, the solid 25 support is washed to remove unbound candidate nucleic acid ligand. The nucleic acid ligands that bind to the HGF or c-met protein are then released into solution, then reverse transcribed by reverse transcriptase and amplified using the Polymerase Chain Reaction. The amplified candidate mixture is then used to begin the next round of the SELEX process. 30 In the above embodiments, the solid support can be a nitrocellulose filter. Nucleic acids in the candidate mixture that do not interact with the immobilized HGF or c-met can WO 01/09159 PCT/USOO/20139 26 be removed from this nitrocellulose filter by application of a vacuum. In other embodiments, the HGF or c-met target is adsorbed on a dry nitrocellulose filter, and nucleic acids in the candidate mixture that do not bind to the HGF or c-met are removed by washing in buffer. In other embodiments, the solid support is a microtiter plate 5 comprised of, for example, polystyrene. In still other embodiments, the HGF or c-met protein is used as a target for Truncate SELEX, described in U.S. Patent Application Serial No. 09/275,850, filed March 24 1999, entitled "Truncation SELEX Method," incorporated herein by reference in its entirety. 10 In preferred embodiments, the nucleic acid ligands thus obtained are assayed for their ability to inhibit the HGF/c-met interaction. In one embodiment, this is accomplished by performing a cell migration assay. Certain cell types, such as A549 lung carcinoma cells, will show increased migration through a Matrigel-coated filter insert (Becton Dickinson) in the presence of HGF. Thus, the degree of inhibition of HGF 15 activity in the presence of an HGF or c-met nucleic acid ligand can be assayed by determining the number of cells that have migrated through the filter in the presence of HGF. Methods and compositions for using nucleic acid ligands to HGF and c-met to treat and 20 diagnose disease Given that elevated levels of c-met and HGF are observed in hypertension, arteriosclerosis, myocardial infarction, and rheumatoid arthritis, nucleic acid ligands will serve as useful therapeutic and diagnostic agents for these diseases. In some embodiments, inhibitory nucleic acid ligands of HGF and c-met are administered, along 25 with a pharmaceutically accepted excipient to an individual suffering from one of these diseases. Modifications of these nucleic acid ligands are made in some embodiments to impart increased stability upon the nucleic acid ligands in the presence of bodily fluids. Such modifications are described and enabled in the SELEX applications cited above. In other embodiments, nucleic acid ligands to HGF and c-met are used to measure 30 the levels of these proteins in an individual in order to obtain prognostic and diagnostic information. Elevated levels of c-met and HGF are associated with tumors in the liver, WO 01/09159 PCT/USOO/20139 27 breast, pancreas, lung, kidney, bladder, ovary, brain, prostrate, and gallbladder. Elevated levels of HGF and c-met are also associated with myeloma. In other embodiments, nucleic acid ligands that inhibit the HGF/c-met interaction are used to inhibit tumorigenesis, by inhibiting, for example, angiogenesis and 5 motogenesis. In one embodiment of the instant invention, a nucleic acid ligand to HGF is used in combination with nucleic acid ligands to VEGF (vascular endothelial growth factor) and/or bFGF (basic fibroblast growth factor) to inhibit tumor metastasis and angiogenesis. The use of multiple nucleic acid ligands is likely to have an additive or synergistic effect 10 on tumor suppression. Nucleic acid ligands that inhibit VEGF are described in U.S. Patent No. 5,849, 479, U.S. Patent No. 5,811,533 and U.S. Patent Application Serial No. 09/156,824, filed September 18, 1998, each of which is entitled "High Affinity Oligonucleotide Ligands to Vascular Endothelial Growth Factor," and each of which is specifically incorporated herein by reference in its entirety. Nucleic acid ligands to VEGF 15 are also described in U.S. Patent No. 5,859,228, U.S. Patent No. 6,051,698, U.S. Patent Application Serial No. 08/870,930, filed June 6, 1997 and U.S. Patent Application Serial No. 09/254,968, filed March 16 1999, each of which is entitled "Vascular Endothelial Growth Factor (VEGF) Nucleic Acid Ligand Complexes, and each of which is specifically incorporated by reference in its entirety.. Nucleic acid ligands to bFGF are described in 20 U.S. Patent No. 5,639,868 and U.S. Patent Application Serial No. 08/442,423, filed May 16, 1995, both entitled "High Affinity RNA ligands for Basic Fibroblast Growth Factor," each of which is specifically incorporated herein by reference in its entirety. Nucleic acid ligands to integrins 25 The SELEX process can be performed using purified integrins, or fragments thereof as a target. Alternatively, full-length integrins, or discrete domains of integrins, can be produced in a suitable expression system. Alternatively, the SELEX process can be performed using as a target a synthetic peptide that includes sequences found in an integrin. Determination of the precise number of amino acids needed for the optimal 30 nucleic acid ligand is routine experimentation for skilled artisans.

WO 01/09159 PCT/USOO/20139 28 In preferred embodiments, the SELEX process is carried out using integrins attached to polystyrene beads. A candidate mixture of single stranded RNA molecules is then contacted with the beads. In especially preferred embodiments, the single stranded RNA molecules have a 2'-fluoro modification on C and U residues, rather than a 2'-OH group. 5 After incubation for a predetermined time at a selected temperature, the beads are washed to remove unbound candidate nucleic acid ligands. The nucleic acid ligands that bind to the integrin are then released into solution, reverse transcribed by reverse transcriptase and amplified using the Polymerase Chain Reaction (PCR). The amplified candidate mixture is then used to begin the next round of the SELEX process. Example 5 illustrates one 10 possible way of performing the SELEX process using integrins as targets. In preferred embodiments, the nucleic acid ligands thus obtained are assayed for their ability to inhibit the interaction of the integrin with its cognate ligand. In one embodiment, this is accomplished by first coating microtiter plates with the appropriate integrin(s). A ligand for the integrin, such as vitronectin or fibrinogen, is then biotinylated 15 and contacted with the coated integrin in the presence of the nucleic acid ligand to be assayed. After incubation for a suitable period of time, the microtiter plate is washed, and the amount of vitronectin or fibrinogen binding to integrin is quantitated by adding a streptavidin-alkaline phosphatase conjugate, followed by a colorimetric substrate for alkaline phosphatase, such as p-nitrophenyl phosphate. The alkaline phosphatase signal in 20 each well of the plate is thus inversely proportional to the effectiveness of the nucleic acid ligand as an inhibitor of the interaction between the bound integrin and its cognate ligand. In other embodiments, the nucleic acid ligands are analyzed using binding to human platelets as an assay. This can be done, for example, by fluorescently labeling the nucleic acid ligand by any of the numerous techniques known in the art. The fluorescent nucleic 25 acid ligand is then contacted with platelets, and the amount of nucleic acid ligand is be quantitated using Fluorescence Activated Cell Sorting (FACS). The distribution of the nucleic acid ligands of the instant invention can also be studied in vivo. In some embodiments, nucleic acid ligands are labeled with a radiolabel used in the art of radioimaging. For example, a nucleic acid ligand can be conjugated to 30 the isotope 99 mTc using one of a number of techniques known in the art. The radiolabelled nucleic acid can then be studied in an animal model of venous thrombosis. For example, a WO 01/09159 PCT/USOO/20139 29 human blood clot can be generated in rabbit vein by first isolating the vein in situ by ligation, and then infusing the vein with human platelet-rich plasma and heparin to induce the formation of a blood clot. Blood flow through the vein is then re-established, and the radiolabelled nucleic acid ligand is introduced into the animals blood supply. The 5 distribution of the radiolabelled nucleic acid ligand can then be studied in the rabbit's tissues to determine whether the nucleic acid ligand has accumulated in the clot, rather than in other areas. Methods and compositions for using nucleic acid ligands to integrins to treat and diagnose 10 disease The nucleic acid ligands provided by the instant invention have a number of potential uses as therapeutic and diagnostic agents. In some embodiments, nucleic acid ligands that inhibit the interaction between platelet-expressed integrins and their cognate ligands are administered, along with pharmaceutically accepted excipients, in order to 15 prevent the formation of blood clots in patients susceptible to deep vein thrombosis. In other embodiments, the nucleic acid ligands are used to treat acute thrombosis formation during and following percutaneous coronary intervention. In still other embodiments, the nucleic acid ligands of the invention are used to treat patients with acute coronary syndromes such as unstable angina or myocardial infarction. 20 In other embodiments, radiolabelled nucleic acid ligands to platelet-expressed integrins are administered to individuals who are to undergo major surgery, or have suffered major trauma. Such nucleic acid ligands can function as imaging agents for the detection of thrombi, by showing sites in the body where large aggregations of platelets are present. If a thrombosis is detected by radioimaging at a critical site in the body, then 25 anticoagulant and thrombolytic treatment --including treatment with the inhibitory nucleic acid ligands of the instant invention-- can be given locally. The advantage of using such a nucleic acid ligand imaging agent is that the anticoagulant and thrombolytic treatments which can cause harm if administered prophylactically by allowing internal bleeding to continue without efficient clotting-- can be given only to those individuals who definitely 30 have a dangerous thrombosis. Moreover, these treatments can be specifically injected at the site where the thrombosis has been detected by the nucleic acid ligand, instead of WO 01/09159 PCT/USOO/20139 30 injecting higher concentrations into the bloodstream in the hope that some active agent will be carried to all potential sites of thrombosis. Nucleic acid ligands to caxp integrin can be used to inhibit tumor growth and metastasis. They can also be used to treat ocular diseases including, but not limited to, 5 diabetic retinopathy, retinopathy of prematurity, and macular degeneration. Other diseases for which cap 3 nucleic acid ligands are useful therapeutic agents include, but are not limited to, endometriosis, psoriasis, rheumatoid arthritis, stroke, osteoporosis, and restenosis. The following examples are given by way of illustration only. They are not to be 10 taken as limiting the scope of the invention in any way. Examples Example 1. Generation of nucleic acid ligands to HGF and c-met 15 Materials and Methods In the sections below entitled "Results: HGF" and "Results: c-met", the following materials and methods were used. Proteins. The HGF protein and c-met-IgGI-His 6 fusion protein, which were used in the SELEX process, and the KDR-IgG,-His 6 proteins were purchased from R&D Systems, 20 Inc. (Minneapolis, MN). The human c-met-IgG,-His 6 fusion protein --described from the amino to the carboxyl terminus-- consists of 932 amino acids from the extracellular domains of the a and p chains of c-met, a factor Xa cleavage site, 231 amino acids from human IgG 1 (Fc domain), and a (His) 6 tag. This protein is referred to in the text and figures as c-met. A similar fusion protein containing the vascular endothelial growth 25 factor receptor KDR will be referred to as KDR. Anti-HGF monoclonal antibody MAB294 was purchased from R&D Systems, Inc. Human IgG 1 was produced in-house by stable expression from Chinese hamster ovary cells. SELEX templates and primers. Standard SELEX templates carrying 30 or 40 30 random nucleotides flanked by fixed regions of the N7 or N8 series and associated primers (Figure 1) were used as described (Fitzwater and Polisky (1996) Methods Enzymol.

WO 01/09159 PCT/USOO/20139 31 267:275-301). Truncate SELEX was done by the hybridization method described in U.S. Patent Application Serial No. 09/275,850, filed March 24 1999, entitled "Truncation SELEX Method," incorporated herein by reference in its entirety, using RNaseH cleavage primers (Figure 2). 5 SELEX methods. Initial HGF SELEX experiments were done by two closely related partitioning methods, both involving separating free from bound RNA on nitrocellulose filters. Conventional SELEX involves mixing target protein and RNA library in HBSMC buffer (hepes-buffered saline, 25 mM hepes, 137 mM NaCl, 5 mM KCl plus 1 mM CaCl 2 , 1 mM MgCl 2 , pH 7.4), followed by filtration on nitrocellulose under 10 vacuum. Maintaining vacuum, the filter is washed in buffer, followed by vacuum release and RNA extraction. In spot filter SELEX, the protein is applied to a dry nitrocellulose 13 mm filter, allowed to adsorb for several minutes, then pre-incubated in Buffer S (HBSMC buffer plus 0.02% each of ficoll, polyvinylpyrrolidone, and human serum albumin) for 10 minutes at 37*C to remove unbound protein. The wash buffer is removed, and then the 15 RNA library is added in the same buffer, and incubated with the protein-bound filter. The filters are washed by repeated incubations in fresh buffer, followed by RNA extraction. SELEX was initiated with between 1 and 5 nmoles of 2'-fluoro-pyrimidine RNA sequence libraries containing either a 30 or 40 nucleotide randomized region sequence (Figure 1). The RNA libraries were transcribed from the corresponding synthetic DNA 20 templates that were generated by Klenow extension (Sambrook, Fritsch et al. (1989) 3:B. 12). The DNA templates were transcribed in 1 mL reactions, each containing 0.25 nM template, 0.58 pM T7 RNA polymerase, 1 mM each of ATP and GTP, 3 mM each of 2'-F CTP and 2'-F-UTP, 40 mM Tris-HCl (pH 8.0), 12 mM MgCl2, 1 mM spermidine, 5 mM DTT, 0.002% Triton X-100 and 4% polyethylene glycol (w/v) for at least 4 hours at 37 0 C. 25 The full-length transcription products were purified by denaturing polyacrylamide gel electrophoresis. Radiolabeled RNA was obtained from transcription reactions as described above, but containing 0.2 nM ATP and 100 ptCi of c 3 P-ATP. Alternatively, radiolabeled RNA was obtained by labeling the 5'-end of RNA with a- 32 P -ATP (NEN-DuPont), catalyzed by T4 polynucleotide kinase (New England Biolabs). To prepare RNA 30 containing 5'-OH groups for kinase reactions, transcription reactions included 5 mM guanosine.

WO 01/09159 PCT/USOO/20139 32 For conventional filter SELEX, radiolabeled RNA pools were suspended in HBSMC buffer to which HGF protein was added, and incubated at 37*C for 30 minutes to 3 hours depending on the round. Binding reactions were then filtered under suction through 0.45 ptm nitrocellulose filters (Millipore), pre-wet with binding buffer. The filters were 5 immediately washed with at least 5 mL of HBSMC buffer. For each binding reaction, a protein-minus control reaction was done in parallel in order to determine the amount of background binding to the filters. The amount of RNA retained on the filters was quantified by Cherenkov counting, and compared with the amount input into the reactions. Filter-retained RNA was extracted with phenol and chloroform, and isolated by ethanol 10 precipitation in the presence of 1-2 ptg glycogen. The isolated RNA was subsequently used as a template for avian myeloblastosis virus reverse transcriptase (AMV-RT, Life Sciences) to obtain cDNA. One hundred pmoles of the 3'-primer (Figure 1) was added to the RNA and annealed by heating for 3 minutes at 70*C, followed by chilling on ice. The 50 iL reaction contained 5 U AMV 15 RT, 0.4 mM each of dNTPs, 50 mM Tris-HCl (pH 8.3), 60 mM NaCl, 6 mM Mg(OAc) 2 , and 10 mM DTT, which was incubated for 45 minutes at 48*C. The cDNA was amplified by PCR with the 5'- and the 3'-primers (Figure 1), and the resulting DNA template was transcribed to obtain RNA for the next round of SELEX. To minimize selection of undesirable nitrocellulose-binding sequences, beginning in 20 round three, pools were pre-soaked with nitrocellulose filters before incubating with the target protein. This treatment worked well to control background binding and helped ensure that each SELEX round had a positive signal/noise ratio. The progress of SELEX was monitored by nitrocellulose filter-binding analysis of the enriched pools (see below). Truncate SELEX was performed by the hybridization method described in U.S. 25 Patent Application Serial No. 09/275,850, filed March 24 1999, entitled "Truncation SELEX Method," incorporated herein by reference in its entirety. Briefly, 2'-F-RNA pools were body-labeled during transcription and cleaved by RNaseH using specific cleavage primers to remove the fixed sequences from the SELEX pool (Figure 2). This RNA was then bound to target protein HGF and recovered following partitioning as in a 30 conventional filter SELEX experiment. The recovered RNA was then biotinlyated at its 3' end and hybridized overnight under appropriate conditions with single-stranded full-length WO 01/09159 PCT/USOO/20139 33 complementary strand DNA obtained from the starting SELEX pool, from which the RNA had been transcribed. The RNA/DNA complexes were then captured on streptavidin coated magnetic beads and extensively washed to remove non-hybridized DNA. The bound DNA in the captured RNA/DNA complexes was then eluted by heat denaturation 5 and amplified using conventional SELEX PCR primers. To complete the cycle, the resulting DNA was then used as a transcription template for generating RNA to be cleaved by RNaseH, and used in the next round of truncate SELEX. For plate SELEX, a polystyrene well was pre-blocked in 400 pL of blocking agent for 60 minutes at 37"C. The blocking agent was removed and the desired amount of RNA 10 in 100 pL binding buffer was added and incubated for 60 minutes at 37'C. White, polystyrene breakaway wells (catalog #950-2965) used for partitioning were from VWR (Denver, CO). The blocking agents, I-block and Superblock, were purchased from Tropix (Bedford, MA) and Pierce (Rockford, IL), respectively. The preadsorbtion was done to remove any nucleic acids which might bind to the well or the blocking agent. The random 15 and round one libraries were not preadsorbed to plates to avoid loss of unique sequences. C-met protein was diluted in HBSMCK (50 mM HEPES, pH 7.4, 140 mM NaCl, 3 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 ), and was adsorbed to polystyrene wells by incubating 100 pL of diluted protein per well for 60 minutes at 3 7"C. The wells were each washed with three 400 pL aliquots of HIT buffer (HBSMCK, 0.1% I-block, 0.05 % Tween 20), 20 and then blocked in 400 p1 of blocking agent for 60 minutes at 37 0 C. SELEX was initiated by incubating 100 pL of RNA in the protein-bound well for 60 minutes at 37"C. The RNA was removed and the wells were washed with 400 pL aliquots of HIT buffer. Increasing numbers of washes were used in later rounds. The wells were then washed twice with 400 pL water. RNA bound to c-met was eluted by adding 100 pL water and 25 heating at 95'C for 5 minutes and then cooled on ice, followed by reverse transcription. Nitrocellulose filter-binding. In binding reactions, RNA concentrations were kept as low as possible --between 1 and 20 pM-- to ensure equilibrium in conditions of protein excess. Oligonucleotides were incubated for 15 minutes at 37'C with varying amounts of the protein in 43 pL of the binding buffer. Thirty-two microliters of each binding mixture 30 was placed on pre-wet 0.45 ptm nitrocellulose filters under suction. Each well was immediately washed with 0.5 mL binding buffer. The amount of radioactivity retained on WO 01/09159 PCT/USOO/20139 34 the filters was quantitated by imaging. The radioactivity that bound to filters in the absence of protein was used for background correction. The percentage of input oligonucleotide retained on each filter spot was plotted against the corresponding log protein concentration. The nonlinear least square method was used to obtain the 5 dissociation constant (Kd; reference Jellinek, Lynott et al. (1993) Proc. Natl. Acad. Sci. USA. 90:11227-3 1). Competitor titration curves were generated essentially as a standard binding curve, except that the protein and RNA concentrations were kept constant, and the competitor concentration was varied. Competitors were also added at a fixed concentration in binding 10 experiments to increase stringency for purposes of comparing pool binding affinities. In these experiments, the competitor concentration was chosen based on the results from the competitor titration curves. Molecular cloning and DNA sequencing. To obtain individual sequences from the enriched pools, the PCR products from the final SELEX rounds were cloned using one of 15 two blunt-end cloning kits: Perfectly Blunt (Novagen, Madison, WI), or PCR-Script (Stratagene, La Jolla, CA). Clones were sequenced with the ABI Prism Big Dye Terminator Cycle Sequencing kit (Perkin-Elmer Applied Biosystems, Foster City, CA). Sequences were obtained from an automated ABI sequencer, and text files were collated and analyzed by computer alignment and inspection. 20 Boundary determinations. 5' and 3' boundaries of RNA aptamers were determined by the method of partial alkaline hydrolysis as described (Jellinek, Green et al. (1994) Biochemistry. 33:10450-6). Cell assays. Standard cell culture procedures were employed in the course of performing in vitro experiments to test aptamer-mediated inhibition of HGF activity. For 25 cell migration assays, monolayers of A549 (lung carcinoma) cells were grown on the top sides of Matrigel-coated filter inserts (Becton Dickinson, Franklin Lakes, NJ) in 24-well plates. The cells adhere to the upper surface of the filter, which is placed in growth medium containing HGF. After two days, the cells are physically removed from the top surface of the filter. The filter is then removed from the insert and stained with crystal 30 violet. Since all cells on the top of the filter are gone, the only cells that remain are those WO 01/09159 PCT/USOO/20139 35 that are have migrated to the bottom of the filter. In the presence of HGF, significantly more cells are found on the bottom of the filter compared to controls without HGF. Oligonucleotide synthesis and modification. RNA was routinely synthesized by standard cyanoethyl chemistry as modified (Green, Jellinek et al. (1995) Chem Biol. 5 2:683-95). 2'-Fluoro-pyrimidine phosphoramidite monomers were obtained from JBL Scientific (San Luis Obispo, CA); 2'-OMe purine, 2'-OH purine, hexyl amine, and the dT polystyrene solid support were obtained from Glen Research (Sterling, VA). For addition of 40K(40,000)-PEG, RNA oligomers were synthesized with an amino linker at the 5'-position. This was subsequently reacted with NHS-ester 40K-PEG 10 manufactured by Shearwater Polymers, Inc. (Huntsville, AL), and purified by HPLC on a reverse-phase preparative column. 2'-O-methyl purine substitution Determination of which 2'-OH-purines can be substituted by 2'-OMe purine was done as described (Green (1995) Chem Biol. 2:683-95). Briefly, a set of oligonucleotides was synthesized with a mixture of 2'-OMe amidites and 15 2'-OH amidites at defined purine positions. The set was designed so that each oligonucleotide contains a subset of partially-substituted purines, and the complete set encompasses all purines. Each aptamer was 5'-end labeled and subjected to limited alkaline hydrolysis followed by binding to HGF protein at two different concentrations, 50 and 100 pM. Following binding, protein-bound RNA was separated by standard 20 nitrocellulose filtration. Bound RNA was recovered and analyzed by high-resolution gel electrophoresis. The fragmented alkaline-hydrolyzed aptamers which were not exposed to HGF were run to establish the cleavage patterns of the unselected aptamers. Hydrolysis occurs only at 2'-OH-purines. If a given position requires 2'-OH for optimal binding to HGF, it appears as a relatively darker band compared to the unselected aptamer at that 25 position. Example 2. Results - HGF Five HGF SELEX experiments were done in total. The first three were done by conventional filter SELEX, while the latter two were done by the hybridization truncate 30 SELEX method described in U.S. Patent Application Serial No. 09/275,850, filed March 24 1999, entitled "Truncation SELEX Method," incorporated herein by reference in its WO 01/09159 PCT/USOO/20139 36 entirety. HGF SELEX 1 was done with 30N7 2'-F-RNA for thirteen rounds of conventional filter binding. HGF SELEX 2 was done with 30N8 2'-F-RNA for thirteen rounds of conventional filter binding. HGF SELEX 3 was done with 30N7 2'-F-RNA for seven rounds by spot filter binding, followed by eight rounds of filter binding. HGF 5 SELEX 4 was done by hybridization filter SELEX for three rounds, starting with pool 8 from HGF SELEX 1. HGF SELEX 5 was done by hybridization filter SELEX for three rounds, starting with pool 11 from HGF SELEX 3. HBSMC buffer was used in conventional SELEX reactions, and in spot filter SELEX, blocking agents were added as described in Materials and Methods. 10 RNA pool binding with and without competitors heparin and tRNA. To evaluate SELEX progress, binding curves with purified HGF protein were routinely done with evolved pools during the course of these experiments. Representative binding curves are shown for HGF SELEX experiments 1 and 2 (Figure 3). These data were used to ascertain when SELEX was complete in that further progress was not likely to occur by performing 15 additional rounds. HGF SELEX 1 reached its maximal binding by round 8, with a binding affinity of approximately 0.1 nM'(Figure 3A; earlier rounds and round 9 were examined in other experiments). HGF SELEX 2 reached its maximal binding by round 10, with a binding affinity of approximately 0.1 nM (Figure 3B). HGF SELEX 3 reached its maximal binding by round 11, after seven rounds of spot filter partitioning followed by 20 four rounds of conventional filter SELEX (see Figure 4B). A SELEX experiment which was deemed complete was characterized by cloning and sequencing (see below). HGF, like other proteins which have large clusters of positively charged amino acids, exhibits a high degree of non-specific binding to polyanionic compounds. For example, random RNA pools bind to HGF with low nanomolar affinity, similar to the 25 value reported for HGF binding to heparin, a polyanionic sulfated polysaccharide known to have an important biological role in HGF function (Zioncheck, Richardson et al. (1995) J Biol Chem. 270:16871-8). Competition binding to heparin as well as the non-specific competitor tRNA was done to provide an additional means of evaluating SELEX progress. This was done because the binding of random and evolved RNA pools to HGF occurs in a 30 high-affinity range that makes it difficult to monitor progress. In other words, random WO 01/09159 PCT/USOO/20139 37 RNA binds so well to HGF that the affinity enhancement of the evolved pools may not be adequately assessed in conventional binding experiments in the absence of competitor. RNA pools from HGF SELEX 3 were subjected to competition with heparin (Figure 4A). This experiment demonstrates that random RNA is considerably more sensitive to 5 competition for binding to HGF than are the evolved pools. These data are compared to those obtained from a binding curve with the same three RNA pools (Figure 4B). In the absence of heparin competition, binding of random RNA to HGF is nearly as good as that of the evolved pools, whereas the heparin competition reveals that the evolved pools are significantly different in composition from random RNA. In addition, while rounds 8 and 10 11 are indistinguishable in conventional binding curves, round 11 exhibits improved binding based on increased resistance to heparin competition. These data contributed to the choice of round 11 as the maximally binding pool from which we cloned and sequenced. A similar, but more pronounced, effect was observed with tRNA as the competitor 15 (Figure 5A). These data indicate that the round 11 pool from HGF SELEX 3 are at least four orders of magnitude more resistant to competition for binding to HGF than is random RNA. From these curves, it was determined that 800 nM tRNA is the maximum concentration at which complete binding of evolved RNA persists. Therefore, binding curves were done at this tRNA concentration to compare the binding of different evolved 20 pools (Figure 5B). These curves were useful in determining that further SELEX rounds beyond round 11 did not improve binding. Typical data from a similar set of binding competition experiments done for latter rounds of HGF SELEX 1 are summarized in Table 1. Cloning and sequence analysis of HGF SELEXes 1, 2 and 3. Following 25 determination of pool binding affinities for HGF, the optimal SELEX pools were cloned and sequenced in order to isolate and characterize individual aptamers. Data from 30N7 HGF SELEX 1 and 3 are summarized in Table 2, including binding affinities for many of the aptamers. A similar data set was generated for 30N8 HGF SELEX 2 (Table 3). Sequences from HGF SELEX 1, 2 and 3 are designated 8-seq. number, 10-seq. number, 30 and 11-seq. number, respectively, referring to the total number of SELEX rounds each cloned pool was subjected to. Sequences were analyzed and organized into groups with WO 01/09159 PCT/USOO/20139 38 significant homology. Motifs were analyzed and predicted structures were drawn in order to analyze key features responsible for binding to HGF. Inhibition of HGF-mediated stimulation of cell proliferation. HGF, while not a potent mitogen, does stimulate moderate proliferation of many cell lines, which can be 5 measured by incorporation of 3 H-thymidine. The inhibitory activity of HGF aptamers was assayed by measuring their effect on proliferation of human umbilical vein endothelial cells (HUVECs), or monkey bronchial epithelial (4MBr-5) cells. Based on the binding data and sequence family analysis, fourteen aptamers were chosen for analysis in vitro because they bind to HGF with high affinity and are representative of different sequence 10 families. The sequences are shown in Table 4, aligned by a rough consensus that contains bases in common to several families. All sequences are 30N7 except 10-2 which is 30N8. HGF stimulates proliferation of HUVECs by about two-to-three-fold (data not shown). The initial experiment indicated that aptamers 8-17, 8-102, 8-104, 8-122, 8-126, 10-2 and 11-208 were effective inhibitors of HGF-induced HUVEC proliferation with Ki 15 values in the low nanomolar range (Figure 6). Aptamers 8-113 and 11-222 were less effective and 8-151 exhibited little or no concentration-dependent inhibition. The latter observation is consistent with the fact that aptamer 8-151 does not bind HGF with high affinity and actually binds worse than the random pool. The following approaches were taken to reduce the length of aptamers which 20 retained significant inhibition of HGF: 1) boundary determinations by biochemical separation of partially hydrolyzed aptamers; 2) sequence motif analysis and educated guessing; and 3) truncate SELEX. Boundaries and truncation. Boundary determinations were done for a subset of aptamers that demonstrated in vitro inhibition of HGF activity. Using a standard alkaline 25 hydrolysis procedure with 5'-end-labeled RNA, the 3'-boundaries of aptamers 8-17, 8-102, 8-104, 8-126, 10-1 and 10-2 were examined. Additionally, 3'-end-labeled RNA was used for 5'-boundary experiments with aptamers 8-17 and 8-102. These experiments were mostly uninformative, probably because the high degree of non-specific binding of RNA fragments, regardless of size, obscured the binding of truncated high-affinity aptamers to 30 HGF. Non-specific binding of virtually all fragments gave no boundary information, and reducing the protein concentration did not help. Instead, we tried to use polyanionic WO 01/09159 PCT/USOO/20139 39 competitors tRNA and heparin to eliminate nonspecific binding to reveal the actual boundaries. The competitors reduced non-specific binding, and HGF was predominantly bound only by full-length aptamers, revealing no boundary information beyond the possibility that full-length aptamers are strongly preferred. 5 The sole exception was aptamer 8-102 which had a plausible 3'-boundary between two possible endpoints which made sense with respect to computer-predicted structures (Figure 7A). Based on the boundary data and structural data, two truncates of aptamer 8 102 were synthesized and analyzed for binding to HGF. The sequence of the full-length aptamer and the two truncates are shown, with fixed regions underlined: 10 aggaggacgauscgaegagugccuguuuaugucaucguccgucgucagacgacucaccega (8-102) (SEQ ID NO:12) ggacgaugcggcgagugccuguuuaugucaucgucc (36mer) (SEQ ID NO: 13) gacgaugcgcgagugccuguuuauguc (28mer) (SEQ ID NO:14) In binding to HGF, the 36mer bound almost as well as the full-length aptamer, while 15 the 28mer bound no better than random 30N7 (Figure 7B), suggesting that the boundary data were correct. Truncation by sequence structure prediction Several attempts were made to base truncation on motif analysis and predicted structures, but these did not succeed in producing truncates which retained binding to HGF. For example, aptamer 8-17 folded 20 into a reasonable predicted structure which suggested two obvious points of truncation from its 3' terminus, into a 38mer or 28mer (Figure 8A). However, binding analysis revealed that neither of these truncates retained significant binding to HGF (Figure 8B). These data suggest either that the predicted structure is incorrect or that some of the 3' region past base 38 is critical for high-affinity binding of aptamer 8-17 to HGF. These two 25 hypotheses are not mutually exclusive. Nevertheless, we did not succeed in obtaining a useful truncate of 8-17 by boundary and structural prediction. Truncate SELEX. In order to generate additional short aptamers, advanced rounds of the earlier SELEX experiments were subjected to additional rounds of truncate SELEX, using the Truncation SELEX method described in U.S. Patent Application Serial No. 30 09/275,850, filed March 24 1999, entitled "Truncation SELEX Method," incorporated herein by reference in its entirety. Binding of RNaseH cleaved pools was examined to WO 01/09159 PCT/USOO/20139 40 determine which were the appropriate rounds to use to initiate truncate SELEX (data not shown). None of the RNaseH-cleaved evolved pools was clearly superior to another in binding to HGF, therefore, the pools which had been previously cloned were chosen to use in truncate SELEX. The encouraging result from this experiment was that after RNaseH 5 treatment, the evolved pools bound better to HGF than did random RNA, suggesting that even in the absence of the fixed regions, significant binding affinity was retained. This observation was sufficient evidence to suggest that truncate SELEX could enrich for sequences that bound to HGF in the absence of fixed regions. Three rounds of hybridization truncate SELEX were done in parallel, using as 10 starting pools HGF SELEX 1 round 8 and HGF SELEX 3 round 11. The truncate SELEX rounds were done at equi-molar RNA and protein, starting at 1 nM and decreasing to 0.5 and 0.1 nM. Signal-to-noise ratios were very high during selection. Subsequent manipulations were satisfactory even though the amount of recovered RNA was sub picomolar. 15 To evaluate the progress of the SELEX, binding affinities of truncate rounds two and three were determined and compared to those of the RNaseH-cleaved starting pools (Figure 9). For both SELEXes, the third round pools bound with improved affinity for HGF compared with the earlier rounds. Interestingly, the second rounds did not bind HGF better than the staring material. The dissociation constants for the third round truncate 20 SELEX pools are 1-2 nM, representing a 2-3 fold improvement. While the magnitude of this improvement is not large, it is probably significant since HGF as a target did not easily yield affinity enrichment, probably because of its intrinsically high affinity for RNA. The two pools were cloned and sequenced, and binding affinities were determined 25 (Table 5). The truncated aptamer with the best binding affinity, Tr5 1, is among several sequences which are novel, that is, they were not found in the clones sequenced from the full-length SELEX pools. The emergence of novel sequences suggests that the truncate SELEX succeeded in amplifying aptamers that were relatively rare in the full-length pools. Aptamer Tr51 appeared more frequently than any other sequence, consistent with the 30 observation that it has better binding affinity than any other truncate. Other sequences that WO 01/09159 PCT/USOO/20139 41 appeared multiple times also tend to be those with binding affinities near or better than the pool Kd of 1-2 nM. HGF inhibition by the 36mer aptamer modified with 40K-PEG. The 36mer derivative of aptamer 8-102, described above, was tested for inhibition in vitro in a 4MBr 5 5 cell proliferation assay (Figure 10). Although the 36mer retained high-affinity binding to HGF, it did not retain inhibitory activity in vitro comparable to its parent aptamer 8-102 and aptamer 8-17 (Figure 10). In order to improve the activity of the 36mer, it was tested in a formulation with a 3' dT cap and 5'-40K PEG. The modified aptamer, designated NX22354, was tested for 10 inhibition of HGF-mediated proliferation 4MBr-5 cells (Figure 11 A). The data indicate that the 36mer-PEG aptamer inhibits HGF, and that it performs at least as well as the full length aptamer 8-17, which had previously exhibited the strongest inhibition of all aptamers tested. As expected, the non-PEGylated 36mer did not inhibit HGF, suggesting that the addition of PEG and/or the 3'-cap contribute to the aptamer's bioactivity. This 15 experiment was also done at lower aptamer concentrations, supporting the previous result and showing more clearly that the 36mer-PEG aptamer is a better inhibitor that the 8-17 full-length aptamer (Figure 11B). Also tested by this assay was a non-binding aptamer containing a 3'-dT cap and 5'-40K PEG, the VEGF aptamer NX1838, which had no effect on HGF stimulation (Figure 12). In this same experiment, a non-PEGylated version of 20 NX1838 and the truncate SELEX aptamer Tr5l were shown to have no inhibitory effect on HGF (Figure 12). This suggests that Tr51, similar to the 36mer base aptamer of NX22354, may require 5'-40K-PEG to inhibit HGF function. Inhibition of HGF-mediated stimulation of cell migration. HGF readily stimulates cell movement, hence the name, scatter factor. The inhibitory effect of HGF aptamers was 25 assayed by measuring their effect on A549 cell migration across a Matrigel coated membrane with 8.0 micron pores as described in Materials and Methods (Table 6). The NX22354 aptamer fully inhibited HGF-mediated migration at both 1 and 0.2 ptM concentrations, but at 0.04 tM, the effect was negligible. The monoclonal antibody control (sample 3) was moderately effective at the 1 pg/mL dose, which is above its 30 published EC 50 value of 0.1-0.3 p4g/mL for inhibition of 4MBr-5 cell proliferation.

WO 01/09159 PCT/USOO/20139 42 Combined inhibitory effect of HGF and VEGF aptamers on HUVEC proliferation. It was reported that VEGF and HGF have an additive stimulatory effect on HUVEC proliferation (Van Belle (1998) Circulation. 97:381-90). This effect was observed when VEGF and HGF were added, singly and in combination, to HUVECs, and incorporation of 5 3 H-thymidine was measured (Figure 13). As expected, stimulation by HGF was relatively weak compared with that of VEGF and together, the stimulatory effect was greater than that elicited by VEGF alone. Based on these curves, we chose to add each cytokine at 10 ng/mL for optimal stimulation in the aptamer inhibition experiments. The effect of adding one or both 10 aptamers to the doubly-stimulated cells in the presence of both growth factors was then tested (Figure 14A). It was observed that each aptamer partially inhibits the stimulation and that both aptamers result in complete inhibition. Interestingly, the magnitude of the inhibitory effect of each aptamer roughly corresponds with the magnitude of the stimulation conferred by each cytokine. This observation suggests that the stimulatory 15 effect of each cytokine can be inhibited independently, and that the two cytokines stimulate HUVECs independently. Figures 14B and C depict controls in which each cytokine was administered separately, demonstrating that the HGF and VEGF aptamers do not cross-react, that is, each aptamer affects only the cytokine against which it was selected. For the HGF 20 stimulated cells, inhibition by the HGF aptamer NX22354 was observed, but not by the VEGF aptamer NX1838 (Figure 14B). Conversely, stimulation by VEGF was inhibited by the VEGF aptamer NX1838, but was unaffected by the HGF aptamer NX22354 (Figure 14C). These data, along with the fact that HGF, like VEGF, is an angiogenesis factor make 25 it intriguing to consider dual administration of VEGF and HGF aptamers to treat tumors. Furthermore, the availability of aptamers which inhibit other growth factors suggests further combinations of the VEGF or the HGF aptamer in combination with other aptamers, for example, aptamers that inhibit bFGF, platelet-derived growth factor (PDGF), transforming growth factor beta (TGF), keratinocyte growth factor (KGF), and/or their 30 receptors allowing for the possibility that any combination of these inhibitors may be WO 01/09159 PCT/USOO/20139 43 relevant. The goal is to have an array of aptamer-inhibitors of cytokines and their receptors and to be able to tailor combination treatments for specific disease states. 2'-O-methyl-purine substitution of HGF aptamer NX22354. To improve the stability and pharmacokinetics of NX22354, we determined which of the 17 2'-OH purines could 5 be replaced. This was done by synthesizing four partially substituted 2'-OMe purine variants of the base sequence of NX22354, followed by analysis as described above in the Materials and Methods section. The four partially-substituted oligonucleotides were synthesized with a 1:1 ratio of 2'-OMe amidite:2'-OH amidite (Table 7). The data analysis measures the ratios of the selected to unselected RNA at each substituted purine position, 10 based on quantitation of bands from the gel. The data are summarized by position (Figure 15). At each position, the three unsubstituted aptamers provide an important comparison, which is expressed as an average of the three unsubstituted aptamers with standard deviation represented by the error bars. Points that occur at ratios higher than that of the nearby positions are likely to require 2'-OH for binding. 15 The data strongly indicate that two positions, G5 and A25, do not tolerate 2'-OMe substitution. Two other positions, A3 and G10, show a slight preference above the standard deviation of the unselected RNA. The set of OMe aptamers were also examined for binding to HGF (data not shown). The binding data indicate that the OMel and OMe3 bind as well as the parent 20 unsubstituted 36mer, whereas OMe2 and OMe4 bind do not bind as well. This suggests that the substitutions in OMe2 and OMe4 are less well tolerated with respect to HGF binding in solution, consistent with the fact that OMe2 and OMe4 are substituted at A25 and G5, respectively. To confirm these results, two aptamers were synthesized which are fully 2'-OMe 25 substituted at the apparently well-tolerated positions. The sequences are shown below, with the 2'-OH-purines shown underlined. All other purines have 2'-OMe and the pyrimidines are 2'-fluoro substituted. 4x Sub 2'-OH. GGACGAUGCGGCGAGUGCCUGUUUAUGUCAUCGUCC (SEQ ID NO:186) 30 2x Sub 2'-OH. GGACGAUGCGGCGAGUGCCUGUUUAUGUCAUCGUCC (SEQ ID NO: 187) WO 01/09159 PCT/USOO/20139 44 Sequence 4x Sub 2'-OH contains all four of the 2'-OH-purines in question, while 2x Sub 2'-OH has only the two 2'-OH-purines most likely to be required. Binding of these oligomers to HGF was examined compared to the unsubstituted parent and the fully 2'-OMe substituted RNA (Figure 16). Based on these binding curves, 5 NX22354 tolerates 2'-OMe substitution at all purines except G5 and A25 (aptamer 2x Sub 2'-OH) with minimal loss of binding affinity. The other two positions in question apparently are not required to be 2'-OH since aptamer 4x Sub 2'-OH binds no better than aptamer 2x Sub 2'-OH. Two aptamers have been synthesized with 5'-40K-PEG and a 3'-dT cap: one is fully 10 2'-OMe substituted and the other contains 2'-OH at positions G5 and A25. One of these will presumably supplant NX22354 as the lead HGF aptamer for further testing in vitro and in vivo. Example 3. Results - c-met 15 c-met SELEX. In the c-met plate SELEX experiments, the concentration of nucleic acids was lowered initially, but then raised in later rounds so that the ratio of the nucleic acid to protein would be very high. This was done in order to create conditions of high stringency which may select for higher affinity aptamers. Stringency was also applied by increasing the number of washes. 20 SELEX pool binding. Binding of SELEX pools to c-met was assessed through round 7 (Figure 17). The binding data indicate that the SELEX resulted in about a 20 fold improvement in Kd from 20 nM to 1 nM for both (40N7) (Figure 17A) and (30N8) (Figure 17B) pools. Since the c-met protein used in SELEX is an IgG fusion protein, random 40N7 and 25 round 7c RNA pools, were tested for binding to human IgG 1 and c-met. The binding dissociation constants are set forth in Table 8. The affinity of round 7c RNA for both IgG, and c-met proteins improved about 50-fold. There are several interpretations of this result. Aptamers may have been selected which bind with better affinity to both proteins. This assumes that the difference in binding between IgG, and c-met is due to c-met specific 30 aptamers. However, the two proteins were made in different cell lines that may have different glycosylation patterns which could influence binding. Thus, if the differences in WO 01/09159 PCT/USOO/20139 45 affinity are due to differences between the free IgG, protein and the IgG, domain in c-met, then there might be few if any c-met specific aptamers in the round 7 pool. In order to address these issues further, random and round 5 RNA pools from both libraries were examined for binding to the c-met and KDR proteins (Figure 18). Both of 5 these proteins were made in the same cell line and contain the same IgG,-His 6 sequence. Random RNA from both libraries binds about the same to each protein (Kd = -50 nM). Round 5 from both libraries of c-met SELEX binds better to c-met than to KDR (-100 fold better for the 30N8 pool and 3-fold better for the 40N7 pool). However, round 5 RNA pools do bind better than random RNA to KDR. These results imply that, while 10 there are probably aptamers that bind to human IgG, or (HIS) 6 tag in the round 5 pools, there may also be c-met aptamers. Detection of IgG aptamers by PCR. Another approach for determining if IgG, aptamers are present in the SELEX pools was to subject them to PCR. Predominant IgG, aptamers have been isolated from N7 type libraries that have a known sequence 15 (Nikos Pagratis and Chinh Dang, personal communication). For the PCR, a DNA oligonucleotide: ML-124; 5'-ACGAGTTTATCGAAAAAGAACGATGGTTCCAATGGAGCA-3' (SEQ ID NO: 188), was used that is complementary to the most prevalent N7-series human IgG, aptamer sequence, and differs by only a few bases from most other IgG, 20 aptamers. This PCR primer is the same length as the selected sequence of the major IgG 1 so that it can tolerate mismatches and hybridize to similar sequences. The ML-124 3'-primer: ML-34; 5' CGCAGGATCCTAATACGACTCACTATA-3' (SEQ ID NO: 189), was used with a 5'-primer containing the T7-promoter sequence 25 present in all cloned aptamers to amplify 40N7 series nucleic acids pools: random, la, 2a, 3a and 4a (data not shown). Since IgG, aptamers have not been isolated from an N8 type library, this analysis was not done for the 30N8 SELEX. PCR of random and c-met SELEX round la pools yielded no signal after 20 cycles. However, rounds 2a, 3 a, and 4a had steadily increasing signals that were easily detectable after 10 PCR 30 cycles. Thus IgG, aptamers appeared relatively early in the 40N7 SELEX experiment. For a negative control, PCR was done with a nucleic acid pool from a WO 01/09159 PCT/USOO/20139 46 SELEX known to lack IgGi aptamers. For positive controls, PCR was done with pools from either an N7-based IgG, or CTLA4-IgG, SELEX. IgG, aptamers were first isolated from both of these SELEXes. The negative control had no detectable IgG, aptamers after 20 PCR cycles. The positive controls had detectable signals after 5 10 PCR cycles. C-met aptamers. The sequences of 19 clones from round 7c-40N7 fall into five families with two sequences each, a group with three unrelated members, and six sequences closely related to known IgG, aptamer sequences (Table 9). Thus, at least 6 of the 19 clones (32 %) are human IgG 1 aptamers. This confirms the results of 10 previous analysis that indicated the presence of IgG, aptamers in this SELEX experiment. Of the 13 clones sequenced from round 7b-30N8, six are almost identical, another five are closely related, and two are distinct (Table 10). Nine clones were tested for binding to c-met or KDR, six from the 40N7 series 15 and three from the 30N8 series. These clones were chosen for the following reasons. Clone 7b-4 is the most frequent clone in Family 1 and is representative of almost all of the sequences isolated from the 7b-30N8 library. Clones 7b-10 and 7b-12 are the two clones from the 7b-30N8 library that had different sequences. From the 7c-40N7 pool, the chosen representatives were: Family 1 (clone 7c-1); Family 2 (clone 7c-4); Family 20 3 (clone 7c-23); Family 4 (clone 7c-26); Family 5 (clone 7c-25); and the presumed IgG1 Family (clone 7c-3). Results are shown for only two clones, including 7c-1, which was the only one observed to bind to c-met better than KDR (Figure 19A). Clone 7c-1, which appeared twice in the 40N7 series, may exhibit biphasic binding behavior with a high affinity 25 binding Kd of ~50 pM and a lower affinity binding Kd of-5 nM. All eight other clones bound to KDR as well as to c-met, including 7c-3, which is shown here as representative example (Figure 19B). Clone 7c-3 and all others besides 7c-1 are presumed to be IgG, aptamers. In summary, two clones (identical to 7c-1) out of 32 apparently bind c-met 30 specifically and with high affinity. The remaining clones appear to be IgG, aptamers.

WO 01/09159 PCT/USOO/20139 47 Example 4. Isolation of integrins and integrin ligands UaC3 integrin was isolated from human placenta and purified by immunoaffinity chromatography essentially as described by (Smith and Cheresh (1988) J. Biol. Chem. 263:18726-31). In brief, human placentas were diced and the tissue fragments were 5 extracted in a buffer containing 100 mM octyl-p-D-glucopyranoside detergent (Calbiochem, San Diego, CA). The extract was cleared by centrifugation and applied to an immunoaffinity column (C0 3 -specific monoclonal antibody LM609 affixed to Affi-Gel 10, (Chemicon International, Inc., Temecula, CA)). Protein bound to the column was eluted with a low-pH buffer and fractions were immediately neutralized and analyzed for 10 integrin content by SDS-polyacrylamide gel electrophoresis. Integrin-containing fractions were pooled and aliquots of the purified material were stored at -80*C. Purified human aA3 was also purchased from Chemicon International, Inc, as was human cpp3 integrin. ocbp and fibrinogen were purchased from Enzyme Research Laboratories, Inc. (South Bend, IN). Vitronectin was purified from outdated human plasma according to the 15 procedure of (Yatohgo et al. (1988) Cell Struct. Func. 13:281-92), using heparin affinity chromatography. Example 5. Generation of nucleic acid ligands to integrins A DNA template library of sequence: 20 5'-ttatacgactcactatagggagacaagaataaacgctcaannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn nnnnnnnttcgacaggaggctcacaacaggc-3' (SEQ ID NO: 190) was prepared by chemical synthesis. The italicized nucleotides correspond to a T7 RNA polymerase promoter. There are 40N residues (a, g, t or c). A short DNA primer "3N8": 5'- gcctgttgtgagcctcctgtcgaa-3' (SEQ ID NO:191) 25 was annealed to the template and extended using Klenow DNA polymerase (New England Biolabs, Beverly, MA). The double-stranded DNA product served as a product for T7 RNA polymerase transcription (enzyme obtained from Enzyco, Inc., Denver, CO) to generate a library of random-sequence RNAs. 2'-fluoro-CTP and -UTP were used in place of the 2'-OH-pyrimidines. 30 For application of the SELEX process to ap 3 integrin, the purified protein was diluted 1000-fold from detergent-containing storage buffer into 50 mM MES (2-[N- WO 01/09159 PCT/USOO/20139 48 morpholino]ethanesulfonic acid), pH 6.1, 150 mM NaCl, 2 mM CaCl 2 , to a final concentration of approximately 0.2 ig/mL. 3.2 p polystyrene particles (IDEXX Laboratories, Inc., Westbrook, ME) were added to the diluted protein and the mixture was rotated overnight at 4*C. The beads were collected by centrifugation and blocked by 5 incubation in 3% BSA in MES buffer (above) for one hour at room temperature. Blocked beads were washed several times by resuspension in binding buffer (50 mM Tris-HCl, pH 7.4 (at 37*C), 145 mM NaCl, 4 mM KCl, 1 mM MgCl 2 , 2 nM CaCl 2 , 0.1 mM MnCl 2 , 0.01% BSA). For one round of selection, integrin-coated beads were mixed with RNA and rotated at 37*C for 4 hours to allow equilibration of the RNA with the immobilized 10 protein. The beads were then collected by centrifugation and washed at least 5 times in binding buffer by rapid resuspension and pelleting, without additional incubation. RNAs that remained bound to the beads were eluted overnight at 37"C in binding buffer plus 100 pM cyclic RGD peptide ("cRGD") (GPenGRGDSPCA, Life Technologies, Gibco BRL, Gaithersburg, MD). Eluted RNAs were extracted with phenol, then chloroform:isoamyl 15 alcohol (24:1), and ethanol precipitated. The RNA pellet was resuspended and annealed to primer 3N8 for reverse transcription using avian myeloblastosis virus reverse transcriptase (Life Sciences, Inc., St. Petersburg, FL). The cDNA pool was amplified by the polymerase chain reaction using the 3N8 primer and primer "5N8": 5'-taatacgactcactatagggagacaagaataaacgctcaa-3' (SEQ ID NO: 192) 20 and T. aquaticus DNA polymerase (Perkin Elmer-Cetus, Foster City, CA). Transcription of the PCR product generated an RNA pool to initiate a new round of selection. For the first round of selection 1 nmol of RNA (approximately 6 x 10" sequences) was incubated at 2 p1M concentration with a volume of bead suspension equivalent to 50 pmol of protein (assuming all the integrin had adsorbed to the beads). In subsequent rounds, the 25 concentration of RNA and protein-coated beads were both reduced to demand higher affinity binding interactions. The affinity of individual RNAs and RNA pools for oI was determined by titration of biotinylated RNA with a small quantity of immobilized integrin. Bound RNA was detected through the biotin moiety. Biotinylated RNA was prepared according to standard 30 transcription protocols, but including a 5-fold molar excess of a 5'-biotin-modified GMP over GTP in the reaction mixture. Methods for synthesizing 5'-biotin-modified guanosine WO 01/09159 PCT/USOO/20139 49 nucleotides are described in WO 98/30720 entitled "Bioconjugation of Oligonucleotides," specifically incorporated herein by reference in its entirety. The modified nucleotide is incorporated at the 5' end of the transcript in proportion to its representation in the guanosine pool. 96-well microtiter plates (Immulon 2, Dynatech Laboratories, Inc., 5 Chantilly, VA) were coated overnight at 4*C with 100 iL purified ca p at a concentration of 0.25 ig/mL in 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM MgCl 2 , 2 mM CaCl 2 , 0.1 mM MnCl 2 . Coating concentrations were 0.8 pg/mL for aI3 3 and 0.3 ig/mL for opps. Wells were blocked with 200 pL of a solution of 3% BSA in the same buffer (1 hour at room temperature) then rinsed 3 times with 200 pL binding buffer (50 mM Tris 10 HCl, pH 7.5, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 , 0.1 mM MnCl 2 , 0.1% BSA). Individual RNAs or RNA pools were denatured briefly at 93*C in binding buffer without divalent cations or BSA, then serially diluted in the same buffer. 50 -pL binding buffer containing 2X-concentrations of divalent cations and BSA were added to each well, followed by 50 paL RNA dilution. 15 RNAs were allowed to incubate in the integrin-coated wells at 37*C for 30-60 minutes. Unbound RNAs were removed by 3 rapid washes in binding buffer. To detect bound RNA, 100 pL of a 1:2500 dilution in binding buffer of streptavidin-alkaline phosphatase conjugate (Calbiochem) were incubated in each well for 30 minutes at room temperature, followed by three rapid washes, as above. 100 pL/well p-nitrophenyl 20 phosphate (Sigma Chemical Co., St. Louis, MO) was added and incubated at room temperature for 30 minutes. Color development was monitored by absorbance at 405 nm. Binding data were fit to an equation that describes the fraction of RNA or protein bound as a function of KD, and the total concentrations of RNA and protein in the binding reaction for both monophasic and biphasic binding behavior (Green et al. (1996) Biochem. 25 35:14413-24). A control RNA corresponding to a sequence-scrambled version of aptamer 7.24: 5'-gggagacaagaauaaucgcucaacguugaaugcugcauuauggaguauugaccgcuacaucccuucgaca ggaggcucacaacaggc-3' (SEQ ID NO:193) was used to monitor non-specific binding of RNA under the conditions of the assay. 30 After seven rounds of the SELEX process, the amount of RNA specifically bound to the integrin-coated beads had increased substantially (data not shown). Although WO 01/09159 PCT/USOO/20139 50 immobilized aP 3 showed no detectable affinity for random sequence RNA, the round 7 RNA pool bound with an equilibrium dissociation constant (KD) of approximately 4 x 10 M (Figure 20). The round 7 affinity-enriched pool was cloned and sequences were determined for individual molecules in the mixture. Of 92 sequences obtained, 35 (38%) 5 were very highly related to one another, in many cases differing at no more than a single base position. These sequences are collectively referred to as "Family 1." It is likely that many if not most of these RNAs derived from a single precursor as a result of errors in replication during the RT and PCR steps. Another 25 sequences (27%) shared a short motif (CCUGCC) that defined a second sequence family ("Family 2"). The remaining 32 10 sequences (35%) were not obviously related to sequences in Families 1 or 2 and were thus termed "orphan" sequences. The large percentage of orphan sequences in the round 7 pool suggested that a great deal of sequence complexity remained in the population. Therefore, the SELEX process was continued in the hope of further enriching for high affinity sequences whose representation in the round 7 pool may have been low. Indeed, a 15 substantial improvement in the affinity of the RNA pool was observed after 8 additional rounds of affinity selection (round 15, Figure 20). No further improvement was seen after two more rounds of selection (round 17, Figure 20), so clones were isolated from the round 15 and round 17 RNA pools and the sequences of individual isolates were compared to those obtained at round 7. Twenty-seven of 39 sequences derived from the round 15 20 pool (69%) were members of the highly conserved sequence family, Family 1. Three sequences (8%) could be grouped with Family 2 and 9 sequences (23%) were orphans. All of the 18 sequences isolated from the round 17 pool were members of sequence Family 1. Thus, in this case, additional rounds of the SELEX process served to focus the RNA population on a single high-affinity sequence family that was already predominate at 25 round 7. Table 11 shows the sequences of the major family of 2'-F-pyrimidine RNAs with high affinity for ajA (Family 1). Clone names indicate the selected RNA pool from which each sequence was derived (round 7, round 15 or round 17) followed by a unique clone number. Note that in several cases identical sequences were isolated from different 30 RNA pools; in these cases, both clone names are given. (Clones 17.12A and B were isolated as end-to-end inserts in a single plasmid.) Numbers in parentheses indicate the WO 01/09159 PCT/USOO/20139 51 frequency with which a particular sequence was isolated; if no number is given the clone was obtained only once from the selected RNA pool. Sequences of the 5' and 3' fixed sequence regions common to all of the clones are shown at the top in lower case letters. Gaps have been inserted into many of the sequences to highlight the strong sequence 5 conservation among most of the clones. The length of the random sequence region is shown for each RNA, as well as an estimate of the KD for binding to immobilized ajp 3 , where it was determined (ND = not determined). The KD value provided is generally based on one or the average of two determinations. Family 2 sequences isolated from the avp 3 SELEX are shown in Table 12. The short motif (CCUGCC) held in common among 10 all the sequences is indicated in boldface letters. In Table 13, sequences with no obvious relationship to Families 1 or 2 are shown. Groups of similar sequences with only two (7.41 (SEQ ID NO:279) and 7.93 (SEQ ID NO:291)) or three (7.11 (SEQ ID NO:276), 7.82 (SEQ ID NO:288) and 7.101 (SEQ ID NO:294)) members are also included in Table 13. 15 The substantial affinity improvement between rounds 7 and 15 must be due in part to the loss of lower affinity species from the population; however, the introduction of and selection for higher affinity sequence variants of Family 1 may also have contributed to the overall affinity enrichment of the pool. While the affinity of relatively few sequences from the round 7 pool were measured, their affinities for immobilized ap 3 were generally 20 less than that of RNAs derived from rounds 15 and 17 (Tables 11-13). Example 6. Specificity of the nucleic acid ligands to integrins In general, aptamers selected for high-affinity binding to a particular target protein show relatively weak binding to other related proteins, except in cases where the degree of 25 homology is very high (for example, see (Green et al. (1996) Biochem. 35:14413-24; Ruckman et al. (1998) J. Biol. Chem. 273:20556-67)). Significant homology exists within the families of integrin alpha and beta sub-units, and both alpha and beta sub-units are shared among members of the integrin superfamily. Thus, it was of interest to assess the relative affinity of the as3 aptamers for closely related integrins. The affinities were 30 determined using the methods described above. The Family 1 aptamer 17.16 (SEQ ID NO:249), was chosen as a representative of the major sequence family. Figure 21 shows WO 01/09159 PCT/USOO/20139 52 that aptamer 17.16 bound with identical affinity to purified, immobilized ap 3 and to the platelet integrin, anC3 3 in a 96-well plate binding assay. Although these two proteins share the p3 sub-unit in common, an alignment of the a, and aB amino acid sequences shows only 36% overall sequence identity (Fitzgerald et al. (1987) Biochem. 26:8158-65). Short 5 stretches of exact sequence identity; 5 to 9 amino acids in length, do occur, primarily within four putative calcium-binding domains of each a sub-unit. Binding of aptamer 17.16 to integrin a0p, was also tested. The P5 sub-unit shares 56% sequence identity with p3 and is more closely related to p3 than other members of the beta sub-unit family (McLean et al. (1990) J. Biol. Chem. 265:17126-31; Suzuki et al. (1990) Proc. Nat. Acad. 10 Sci. 87:5354-8). No aptamer binding to immobilized integrin a~p, was observed (Figure 22), although an a,-specific antibody detected the presence of a~p, protein adsorbed to the surface of the well (data not shown). Together, these data strongly suggest that aptamer 17.16, and by extension the other members of sequence Family 1, bind primarily to the 3 sub-unit of aCp 3 . Furthermore, the high-affinity binding of the aptamer to the platelet 15 integrin, aup33 extends its range of potential application to indications involving detection of platelets or inhibition of their function. Example 7. Aptamer inhibition of ligand binding to purified integrins While the SELEX process identifies RNA sequences with high affinity for a 20 particular target, the procedure used in this example was designed to bias for the recovery of ligand binding site inhibitors by the inclusion of a cRGD peptide competitor in the elution buffer. To test whether aptamer 17.16 (SEQ ID NO:249) could block the ligand binding site of a 3 or a 1 bp3, purified vitronectin and fibrinogen were biotinylated and incubated with one or both of the immobilized integrins in the presence or absence of 25 varying concentrations of the aptamer or a non-binding control RNA. This was done as follows: purified integrin ligands, vitronectin and fibrinogen, were biotinylated according to (Smith et al. (1990) J. Biol. Chem. 265:12267-71). Briefly, proteins were dialyzed into 0.1 M NaHCO 3 and 0.1 M NaCl. N-hydroxysuccinimido-LC-biotin (Pierce) was dissolved at 1 mg/mL in DMSO and added to the protein at a ratio of 0.1 mg biotin per 1 mg protein. 30 The reaction was allowed to rotate at room temperature for 2 hours. Biotinylated proteins were dialyzed into phosphate-buffered saline and their concentrations determined by WO 01/09159 PCT/USOO/20139 53 absorbance at 280 nm. 96-well microtiter plates were coated as described above with either 03 or cnsP 3 and blocked with BSA. A fixed concentration of biotinylated ligand (fibrinogen: 6 nM final; vitronectin: 10 nM final) was pre-mixed in binding buffer (see "Measurement of Aptamer Binding Affinities," above) with varying concentrations of 5 aptamer, control RNA, cyclic RGD peptide, antibody, or unmodified ligand. The mixtures were incubated in the integrin-coated wells for 60 minutes at room temperature. After washing, bound biotinylated ligand was detected by addition of 100 PL /well 1:500 dilution streptavidin-alkaline phosphatase conjugate (Calbiochem) (30 minutes at room temperature) followed by 100 pL /well p-nitrophenyl phosphate, as described above. 10 Absorbance was read at 405 nm. The data were fit to an equation that describes mutually exclusive binding of two ligands to a single target species (Gill et al. (1991) J. Mol. Biol. 220:307-24). The concentration of competitor that inhibited 50% of the maximum signal above background (IC 50 ) was determined from the fitted curve. Known ligand binding inhibitors, including an RGD peptide and the CAp3-specific 15 antibody LM609, were included as positive controls for the assay. Figure 23A shows inhibition of biotinylated vitronectin binding to immobilized a3. Aptamer 17.16 inhibited the binding interaction with an IC 5 0 of 4.7 nM while the control RNA showed no inhibition. By comparison, the IC 50 of RGD peptide inhibition was 1.4 nM and that of LM609 was 2.7 nM. Unmodified vitronectin inhibited the binding of the biotinylated 20 material with an IC 50 of 59 nM. Similar data were obtained for aptamer inhibition of fibrinogen binding to a~p3 (Figure 23B) and for fibrinogen binding to CClp (Figure 23C).

IC

50 values for the data in Figure 23B were: 17.16, 9.5 nM; control RNA, not measurable; RGD peptide, 1.0 nM; LM609, 6.3 nM; unmodified fibrinogen, 43 nM. IC 5 0 values for Figure 23C were: 17.16, 6.5 nM; control RNA, not measurable; RGD peptide, 21 nM; 25 unmodified fibrinogen, 15 nM. Thus, aptamer 17.16 is an effective competitor of P3 integrin ligand binding and, on a molar basis, has an inhibitory potency nearly equivalent to that of a bivalent antibody. Example 8. Nucleic acid ligand binding to human platelets 30 Aptamer 17.16 (SEQ ID NO:249) was selected for binding to purified human cvp3 adsorbed to the surface of a polystyrene bead. In vitro assays to measure the affinity of the WO 01/09159 PCT/USOO/20139 54 aptamer for purified p3 integrins were also done in the context of hydrophobically adsorbed protein. Thus, an important test of aptamer function was to determine its capacity to bind to native protein on the surface of cells. Human platelets were chosen for this purpose because of their ease of isolation and their high level of expression of integrin 5 %As3. Because %acp undergoes a conformational change upon platelet activation, binding of the aptamer to both resting and thrombin-activated platelets was tested. This was done as follow: fluorescein-conjugated RNA was prepared according to (Davis et al. (1998) Nuc. Acids Res. 26:3915-24). Briefly, RNA was transcribed in the presence of a 5-fold molar excess of the initiator nucleotide guanosine-5'-O-(2-thiodiphosphate) (Calciochem), 10 followed by conjugation of the gel-purified RNA to 5-iodoacetamidofluorescein (Pierce, Rockford, IL). Platelet-rich plasma was prepared from freshly-drawn citrated human blood by centrifugation at 1000 rpm for 15 minutes in a table top centrifuge. For activated platelets, cells were incubated for 15 minutes at room temperature at 2 x 10 7 /mL in calcium- and magnesium-free Dulbecco's PBS with 2.5 U/mL thrombin and 5 mM Gly 15 Pro-Arg-Pro (GPRP) to inhibit platelet aggregation. Cells were diluted 1:10 into binding buffer (20 mM HEPES, pH 7.5, 111 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 0.1% BSA, 0.0 1% NaN 3 ). Resting cells were diluted similarly, without exposure to thrombin or GPRP. The activation state of resting and thrombin-treated cells was monitored by staining with fluorophore-conjugated antibodies to CD61 (p3 integrin 20 subunit), which binds to all platelets, and to CD62 (P-selectin), a marker of platelet activation. Antibodies were obtained from Becton-Dickinson Immunocytometry Systems, San Jose, CA. Fluorescein-conjugated RNAs were diluted in water to 4 RM and denatured briefly at 93*C, then diluted to 2 pM with 2X-concentrated binding buffer. RNAs were then serially diluted in binding buffer. Each dilution was mixed 1:1 with resting or 25 activated platelets and allowed to incubate in the dark at room temperature for 30 minutes. The incubation mixtures were applied directly to a Becton Dickinson FACSCalibur flow cytometer to determine the mean fluorescence intensity of the sample. Under such equilibrium binding conditions, an estimate of the KD for aptamer binding to the cell surface integrin could be obtained. 30 Non-specific RNA binding to platelets was measured using a control RNA of similar length and base composition to aptamer 17.16. Non-specific binding became significant at WO 01/09159 PCT/USOO/20139 55 concentrations above approximately 100 nM. Specific binding of the aptamer was distinguished from non-specific binding by the addition of 5 mM EDTA to the sample: EDTA had no effect on the binding of the control RNA but reduced aptamer binding to the level of the control. Specific binding of the aptamer was thus defined as the difference 5 between the fluorescence intensity of the sample before the addition of EDTA (specific + non-specific) and the fluorescence intensity after the addition of EDTA (non-specific only). Figure 24 shows representative data for the EDTA-sensitive component of aptamer binding to both resting and thrombin-activated human platelets. The maximum binding 10 signal is approximately 2-fold higher to activated platelets, consistent with the slightly higher level of %acp on such cells (Wagner et al. (1996) Blood 88:907-14). However, the estimated KD for aptamer binding to platelets was approximately 10 nM for both cell populations, equivalent to the value determined for binding in vitro to purified axlbp 3 . Furthermore, aptamer 17.16 binds to both resting and activated platelets with an affinity 15 equivalent to that reported for Reopro (abciximab, chimeric 7E3 Fab), an approved cp3 antagonist (Mousa et al. (1998) J. Pharm. Exp. Ther. 286:1277-84). Example 9. Nucleic acid ligand biodistribution in rabbit venous clot model To explore the application of a p3-specific aptamer in clot imaging, aptamer 17.16 20 was labeled at the 5' end with technitium-99m ( 99 mTc) and its biodistribution was monitored in a rabbit model of venous thrombosis. In this model, a clot is generated in situ in the isolated jugular vein of a rabbit from human platelet-rich plasma. Blood flow across the clot is re-established and the radiolabeled aptamer (or a non-binding control RNA) are introduced into the bloodstream via the ipsilateral ear vein. The distribution of 25 the radiolabel into various tissues is reported as the per cent of the injected dose per gram of tissue. The experiment was performed as follows: Aptamer 17.16 and a control RNA of similar length and base composition were transcribed using a 5-fold molar excess of 5'-(0 hexylamino) guanosine monophosphate. Each RNA was conjugated to Hi, at 50 mg/mL 30 aptamer in 30% dimethylformamide with 5 molar equivalents of Hi 1 ,-NHS buffered in 100 mM NaBorate pH 9.3, for 30 minutes at room temperature. The conjugation reactions WO 01/09159 PCT/USOO/20139 56 were washed over a 30,000 molecular weight cut-off filter (Microcon 30, Amicon, Inc., Beverly, MA) to remove excess Hi 5 cage. The RNAs were then labeled with 9 9 mTc in the following manner: to 1 nmol Hi,,-aptamer was added 200 1 L of 100 mM sodium phosphate buffer, pH 8.5, 23 mg/mL NaTartrate, and 50 iL [ 99 mTc] pertechnetate (5.0 5 mCi) eluted from a 99 Mo column (Syncor, Denver) within 12 hours prior to use. The labeling reaction was initiated by the addition of 10 pL 5 mg/mL SnCl 2 . The reaction mixture was incubated for 15 minutes at 90* C. Unreacted 99 mTc was removed by spin dialysis through a 30,000 molecular weight cut-off membrane (Centrex, Schleicher & Schuell) with two 300 pL washes. This labeling protocol results in 30-50% of the added 10 99 mTc being incorporated with a specific activity of 2-3 mCi/nmol RNA. For biodistribution studies, rabbits were anesthetized with isofluorane. A two centimeter section of the right jugular vein was isolated in situ and all the branches were ligated. A catheter was inserted into the facial vein. The isolated vein segment was temporarily ligated above and below the catheter. The vein segment was flushed with 15 saline. 1000 USP units of heparin was administered intravenously. 300-400 pL of fresh human platelet-rich plasma (citrate) activated with calcium and thrombin was instilled into the isolated vein segment and allowed to clot. After 30 minutes the ligatures were removed and blood flow over the thrombus was re-established (confirmed by the injection of 200 pL of air into the ipsilateral ear vein). [ 99 mTc]-conjugated aptamer or control RNA 20 was injected into the ipsilateral ear vein. At 1 hour the rabbit was exsanguinated and tissues were weighed and counted in a Wallac 1470 gamma counter. The aptamer and control RNA were tested at 1 nmol/kg (approximately 0.03 mg/kg). For aptamer 17.16, radiolabel accumulated in the clot to a significant degree by one hour after injection, while similar accumulation was not observed with the control RNA 25 (Figure 25). Blood clearance of the radiolabel was apparently rapid and mediated primarily by a renal mechanism as judged by moderate accumulation of radioactivity in the kidney for both the aptamer and control RNA. Thus, aptamers specific for am#j 3 or for other proteins expressed at high levels on the surface of platelets or within the matrix of a clot will serve as useful agents for rapid imaging of thrombi.

WO 01/09159 PCT/USOO/20139 57 Table 1. Binding affinities of HGF SELEX 1 pools with and without competitor tRNA. RNA pool Kd (nM) Kd (nM) w/ tRNA Random 30N7 1.6 550 HGF SELEX 1 Rd.8 0.07 0.35 HGF SELEX 1 Rd.9 0.09 0.42 WO 01/09159 PCT/USOO/20139 58 Table 2. HGF 30N7 aptamer sequences and binding affinities. Seq. no.a 30N7 random regionb SEQ ID No: Kd (nM) 8-122 (2,1) CGGUGUGAACCUGUUUAUGUCCGCGUACCC 18 0.097 8-108 CGGUGUGGACCUGUUUAUGUCCGCGUACCC 19 NDC 8-115 AGUGAUCCUAUUUAUGACAUCGCGGGCUGC 20 ND 8-125 UGUGAACCUGUUUAUGUCAUCUUUUGUCGU 21 0.075 8-155 (1,1) UGUGAACCUAUUUAUGCCAUCUCGAGUGCC 22 0.093 8-162 CGUGAGCCUAUUUAUGUCAUCAUGUCUGUC 23 ND 8-165 CGAGAGCCUAUUUAUGUCAUCAUGCCUGUG 24 0.100 8-171 CGGGAGCCUUUUUAUGUCAUCAUGUCUGUG 25 0.120 8-114 (4,2) CGUGAGCCUAUUUAUGUCAUCAUGUCUGUG 26 0.071 8-203 CGCGAGCCUAUUUAUGUCAUCAUGUCUGUG 27 0.140 8-215 CGUGAGCCUAUUUAUGUCAUCAUGUCUGGU 28 0.077 8-217 CGUGAGCCUAUUUACGUCAUCAUGUCUGUG 29 ND 8-222 UGUGAACCUAUUUAUGCCAUUAUGUCUGUG 30 0.130 8-22 5 CGUGAGCCUAUUUAUGUCAUCAAGUCUGUG 31 ND 8-102 CGAGUGCCUGUUUAUGUCAUCGUCCGUCGU 12 0.060 11-9 CGUGAGCCUGUUUAUGACCUCGUCCAUGGC 32 0.074 11-58 CGUGAGCCUAUJUAUGACAUGUCCCUCGAG 33 ND 11-59 CGUGAGCCUGUAUAUGUCAUUGUUCUCCGG 34 0.110 11-57 UGAGUACCUGUUUAUGUCACCACUUUCCCC 35 ND 11-103 UGAUUACCUA UUAUGUC UCGCCCUCUC 36 0.200 11-110 UGAUUACCUAUUUAUGUCAUGCUCCUCCCC 37 0.086 11-65 UGAUAACCUGUUUAUGCCAUCGUGCUGGGC 38 0.110 11-167 UGAUAACCUGUUUAUGUCAUCGUGCUGGGC 39 ND 11-201 UGAGAACCUAUUUAUGUCAUCGUGUCUGGC 40 ND 11-162 UGAUAACCUAUUUAUGACGUCGUGGCUCCC 41 ND 11-202 UGGGAACCUAUUUAUGUCAUC UCCGUCCC 42 ND 11-106 CGAUGAUGCCUGUUUAUGUCGAUGUCCCCC 43 0.120 11-158 CGAUAGCCUAUUUAUGACCUCGUCCCCGUG 44 0.170 11-112 CGUGAGCCUAUUUAUGACAUCGUUCUUGGC 45 ND 11-124 CGUGAGCCUAUCUAUGUCAUCGUGUGUGCC 46 ND 11-122 UGAGUACUAUUUAUGUCGUCGUUCGUGCC 47 ND 11-217 CGUGAGCCUUCCAAUGACGUCGUCCUUGGC 48 0.071 8-104 GCGACUCAAUCUGAAUCGUCUUGUCCCGUG 49 0.050 11-76 UCAGCGGCGCGAGCCUGUUUAUGUC UGCUG 50 0.076 "consensus" CGUGAGCCUAUUUAUGUCAUCGU-C-UG 51 11-8 UCAGUAUGACU UUUAUAGCA CGUUCGCCC 52 0.150 11-153 ACAGGUAGUCU UCUAUAGCA CUUCCUCCCC 53 0.190 11-157 UCAGAAUGACU UUCAUAGCA CGCUUUCCC 54 0.260 11-222 ACAUAAGUCU UCUAUAGC UCGUCCUUUGUG 55 0.077 11-223 UCAGUAUGGCU UCUAUAGC UCGUUCCUCGG 56 0.120 8-126 (3,1) GUGACUCAAAAUGGUGAUCCUCG UUUCCGC 57 0.099 8-101 GUGACUCAAAAUGGUGAUCCUCGAUUUCCGC 58 0.095 8-105 GUGACUCAAAAUGGUGAUCCUCGAUUGCCGC 59 ND 8-103 GCCGAAAAU UCGUCGACAUCUCCCUGUCUG 60 0.120 WO 01/09159 PCT/USOO/20139 59 Table 2. (cont.) Seq. no.a 30N7 random regionb SEQ ID NO: Kd (nM) 8- 118 GGCGACUUUCCUCCAAUUCUCACCUCUGCA 61 0. 160 8-119 GCCAUUCGAUCGA UUCUCCGCCGGAUCGUG 62 0.110 "consensus" CGUGAGCCUAUUUAUGUCAUCGU-C-UG 51 8-3 (2) AUCCCGCGAC CAGGGCGUU UCUUCCUCGUCC 63 0.130 8-112 (3) UCCCGAAUUUAAGUGCGUU UCCUCCGCGUC 64 0.130 8-154 (3) UCCCAAGAUUCAGGGCGUU UCUUCCUCGUC 65 0.120 8-117 UCCCAAGUUUCAGGGCGUU UCUUCCUCGUC 15 0.130 8-123 UCCCGAGUUUGAGGGCGUU UCUUCUUCGUC 66 0.210 11-121 UCCCAGUUUCAgGGGCGAU UCCUCUUCGUC 67 NDc 8-17 (7,1) GCGGCU CGAUG UCGUCUUAUCCCUUUGCCC 68 0.095 8-16 GCGGGCU CGAUG UCGUCUUAUCCCCUUUGCCCC 69 ND 8-158 CCGGCU CGAUG UCGUCUUA CCCCUUUGCCC 70 0.310 11-104 GUUUGAG UGAUG UCGUCUUGUCCCGCCUGC 71 0.091 11-111 GUUAGAG UUUUG UCGUCUUGUCCCAUGUG 72 ND 11-163 GCUUGAGUC UUUG AUCGUCUUAUCCCUCGU 73 0.082 11-208 GUUUGAG UGACG AUCGUCUUGUCCCAUGUG 74 0.060 11-212 GUUUGAG UUAAA CAUCGGUUUUCUCCUG 75 0.075 11-6 GACGCG UUGAUU CAUCGUCUUAUCCUGCUG 76 0.240 11-126 GUUUGGGUCU UGAUC UCGUCUUGUCCCGUG 77 0.170 11-165 gUUGAUAGG AGUCAU CAUCGUCUUGUCCGC 78 0.073 11-215 GUAGUGAG UUUUCAUU GUCUUGUCCCCGUG 79 0.091 11-151 UGAGUCAUAGUGUUG AUCGUCGUAUCCCGU 80 0.170 11-7 GUGGAGUCAA AUCGUCUUGUCCCUUGUCCU 81 0.110 11-166 GUUUGAG UUCUGACA CGUCUUGUCCCAUGC 82 0.079 11-17 GUUAGAGC GUGACAG UCGUCUUAUCCCGGGUCA 83 0.130 8-113 (2) UGAAUUCCUCUGGCUGAAAAU GACUUGUGC 84 0.083 8-60 UGAAUUCCUUUGGCUGAAAAU GACUUGUGC 85 ND 11-221 GCAGAGCGAAAAUCGUCUUGUCCCCGACGC 86 0.062 ORPHANS 11-123 GUGACUCAAAAUGGUGAUCCUCGUUUCGC 87 0.090 8-151 AGGACUAAUCCCUAAGGAAUAGCUUGCCCG 88 8 8-174 UCGAGCUUCUGAGUUAAA CUGGGGCCUCCU 89 0.230 8-160 GUCCCCGAAUUUAAAGUGCGUUUUCCUCCGGG 90 0. 150 11-203 GGUUUUUCUUUUCUUGUUCUCUUCUUUCCCC 91 0.260 11-224 ACAGCGGCGACUAGCCUGUUCAUGCCUGCC 92 0.110 11-107 GUUCUGUGUGUCCACGUUCUUACCCCUGUG 93 0.140 WO 01/09159 PCT/USOO/20139 60 Table 2. (cont.) aClone series 8 is from HGF SELEX 1; series 11 is from HGF SELEX 3. Numbers in parentheses refer to repeat occurrences of the same exact sequence. For the series 8 clones, a second number refers to an exact match which was isolated in series 11. bN7 fixed sequences are not shown. (5'-GGGAGGACGAUGCGG-N CAGACGACUCGCCCGA-3') cND, not determined.

WO 01/09159 PCT/USOO/20139 61 Table 3. HGF 30N8 aptamer sequences and binding affinities. Seq. no.a 30N8 random regionb SEQ ID NO: Kd (nM) 10-28 CCUGUUCUGAAC GCAAAAUGGCGUGGUGGC 94 0.860 10-40 UGUCGUUAGUUUAUUGACAAGGCCCGAAG 95 0.350 10-52 UCUUAUUGUGUCCAGCUUCUCCCUGCAGGC 96 0.160 10-72 UGUGGCAC UGUUGUCCACAAGGGCCUCA 97 0.450 10-8 UUGACAAGGUACCUGUUGCCUGGCGUUUCU 98 0.920 10-76 AGUUAGGCUUAAAGC ACG AUAAUCAGCA 99 0.170 10-47 GUCAAGAGG AAAUGACACGG CUCCACUUUUA 100 0.390 10-2 (10) GCCUGAGUUAAACAUGACGG UUUGUGACCC 101 0.069 10-3 GCCUGAGUUAAACAUGACGGGUUUUGUGACCCCU 102 0.072 10-23 (4) GUCUGAGUUGGACACAACGC AUUGAGACCC 103 0.330 10-24 GUCUGAGUUgGUCACAACGC AUUGAGACCC 104 NDC 10-37 GUCUGAGUCCGU AGGGCGA UUUGUGUCCC 105 3.05 10-7 UGCCUUAAGAGCGGAA CUCCCUGACCCACC 106 1.45 10-13 GAUCUGUUGGCGU GU CUACCCGACCCUCCU 107 0.720 10-17 AACCCUGUUGGCGU GA CGUCCCGACCCUCC 108 0.560 10-36 CGUUAGCAUCUGAACGAUGCCCAGCCUCAA 109 1.94 10-62 GUUAGACUCAACAUGAGUCCCAGCCUCAA 110 0 .440. 10-29 UCUGUUGGCGUCGU UCUCCUGACCCUCCUC 111 1.75 10-48 GAGUUCCCUGUUGAC UCGC UCUCCUGACCC 112 0.310 10-16 UACAGCGUGUUGGUCCCGGACGGGGACUUAU 113 0.210 10-11 CGCCUGGACCGUUUGUUUAUCCCCGUAGUC 114 0.610 10-18 CGUGAUUCCUACCAUCA GGUACCUAUCUUG 115 0.300 10-1 (2) AGUGAUGUGAGAG CGUGCCUCUAGUCGGUG 116 0.094 10-57 CGAGCCUCCUACCGUUU AGGUACC AUCUUG 117 0.140 10-27 UUAGCCUCCGACCG UAA GGUCCUUUUCUUG 118 0.830 10-53 GGCCUCCAACCGCUAAA GGUUCCAUUCUUG 119 0.310 10-49 CCCGACCUCCUGUAACUGGUUGA GGCACUA 120 0.240 10-31 (2) GGGUUCCUGAUUGACCCUGUCUCUAGACCC 121 1.90 10-58 GGGGAGGCCCUUCAGCCGUCUCCUUGACCC 122 0 .440 10-63 UGUGAUGUGAGGGC GUGCUUCCUAACGGUG 123 0.190 40N8 "hitchhiker" sequences 10-19 UUCAUUAUGCAUCGAACAGUAUACCACAGGUGUUCAUGUG 124 ND 10-35 AUCCAAAUUCUGGUCAUGAGGCGCUGCAGAUACUGCUGCG 125 2.33 10-38 UCUGCGGACGGUGAGGUUAAGUUGCAACGACUGCUUGGCG 126 7.38 10-42 CAGACCGUGCAAACCCCCCUUAGAGGGUUUUGUCAUUUAC 127 ND 10-56 CCUUAGGGCUCCCAAAAAUCGGGCC CGUCGGGCCGAUCAC 128 0.280 10-68 CGCGGGAUUCUCUGAGGACGAGGCACGUGUGGGUAAUUCG 129 1.00 10-67 UCGGGCUUGGAUGUGGACGUGUAUUUCUAGCUGUGUACGC 130 0.640 10-4 UUGGGUCGGGACUCGAAAGGAUUUGAUAGGAUACAUGAAU 131 0.610 aClone series 10 is from HGF SELEX 2. Numbers in parentheses refer to repeat occurrences of the same exact sequence. bN8 fixed sequences are not shown. (5'-GGGAGAUAAGAAUAAACGCUCAA-N UUCGACAGGAGGCUCACAACAGGC-3') cND, not determined.

WO 01/09159 PCT/USOO/20139 62 Table 4. List of HGF aptamers and their binding affinities which were tested in vitro for inhibition of activity. Seq. No. random region K_ (nM) SEQ ID NO: "consensus" CGUGAGCCUAUUUAUGUCAUCGU-C-UG 8-17 GCGGCU CGAUG UCGU CUUAUCCCUUUGCCC 0.095 68 8-102 CGAGUGCCUGUUUAUGUCAUCGUCCGUCGU 0.060 12 8-104 GCGACUCAAUCUGAAUCGUCUUGUCCCGUG 0.050 49 8-112 UCCCGAAUUUAAGUGCGUU UCCUCCGCGUC 0.130 64 8-113 UGAAUUCCUCUGGCUGAAAAUGA CUUGUGC 0.083 84 8-122 CGGUGUGAACCUGUUUAUGUCCGCGUACCC 0.097 18 8-126 GUGACUCAAAAUGGUGAUCCUCG UUUCCGC 0.099 57 11-8 UCAGUAUGACU UUUAUAGCA CGUUCGCCC 0.150 52 11-76 UCAGCGGCGCGAGCCUGUUUAUGUC UGCUG 0.076 50 11-166 GUUUGAG UUCUGACA CGUCU UGUCCCAUGC 0.079 82 11-208 GUUUGAG UGACG AUCGUCU UGUCCCAUGUG 0.060 74 11-222 ACAUAAGUCU UCUAUAGC UCGUCCUUUGUG 0.077 55 10-2* GCCUGAG UUAAACAUGACG GUUUGUGACCC 0.069 101 8-151 AGGACUAAUCCCUAAGGAAUAGCUUGCCCG 8 88 *10-2 contains N8 fixed sequences; all others are N7.

WO 01/09159 PCT/USOO/20139 63 Table 5. HGF truncate SELEX 30N sequences. Trunc # of Sequence of random region Identity Kd SEQ Seq #a hits (G)G-30N-CA to full- (nM) ID length b No: GGACGAUGCGGCGAGUGCCUGUUUAUGUCAUCGUCC NX22354 0.1 13 Tr7 (5) CGGUGUGAACCUGUUUAUGUCCGCGUACCC 8-122 0.67 132 Tr45 (3) UGGGAACCUAUUUAUGUCAUCUCCGUCCC 11-202 1.7 133 Tr7O UGGGAACCUAUUUAUGUCAUCGUCUGUGCC New 2.4. 134 Tr6 CGUGAGCCUAUUUAUGUCAUCAUGUCUGUG 8-114 9.0 135 Tr20 UGUGAACCUGUUUAUGCCAUCUCGAGUCCC New 3.4 136 Tr23 UGUGAACCUAUUUAUGCCAUCUCGAGUGCC 8-155 NDc 137 Tr42 UGAUAACCUAUUUAUGACGUCGUGGCUCCC 11-162 6.1 138 Tr44 AGUGAUCCUAUUUAUGCCGUCGCUUCUCGC New 6.5 139 Tr65 AGAGNUCCUAUUUAUGACAUCCCAUGCCCC New 1.4 140 Tr48 UGAUCACCUGUUUAUGCCAUCGUUCUGGGC 11-65 1.8 141 Tr28 GGUGACCCUUUUUAUGACAUCGCGUCUGGC New 4.0 142 Tr5l (6) AAUCACAGGAAUCAACUUCUAUUCCCGCCC New 0.06 143 Tr67 AAUCACAGGAAUCGACUUUUAUUCCUGCCC New ND 144 Trl7 GC GGCUCGAUGUCGUCUUAUCCCUUUGCCC 8-17 3.0 145 Tr27 UC GGCUCGUUGUCGUCUUAUCCCUUUGCCC New ND 146 Trl8 GCUGGCUCGAUGUCAGGUUAUCCCUUUGCCC New ND 147 Tr4 ( 4

,

2 )d GUGACUCAAAAUGGUGAUCCUCGUUUCCGC 8-126 1.4 148 Tr3l (2) UGAAUUCCUCUGGCUGAAAAUGACUUGUGC 8-113 9.2 149 Trl5 GUUUGAGUGACGAUCGUCUUGUCCCAUGUG 11-208 8.8 150 Tr1 AUUGAUUCACUGCAUCCUUGACUCUUCCCC New 7.3 151 Tr5 CAGACGACUCGCCCGAAGGACGAUGCGG New 28 152 Trl4 GAGUUAUAUUUCGUCACCCGUUCCUUUGCCC New 2.2 153 Tr59 ACAGUUUGUCUUCUAUAGCUCGUCGCCCC New 7.2 154 Tr71 UCAGAAUGACUUUCAUAGCUCGCUUUCCCC New 7.7 155 aTr1 -36 and Tr37-72 clones are from series which were carried through 8 and 11 conventional rounds, respectively. bSequences indicated are identical to full length aptamers derived from series 8 or 11; NX22354 is a synthetic truncate based on boundary experiments, derived from sequence 8-102, shown here for comparative purposes. cND, not determined. d( 4

,

2 ) refers to 4 occurrences in the first series and two in the second series.

WO 01/09159 PCT/USOO/20139 64 Table 6. Invasion of A549 cells through Matrigel is inhibited by HGF aptamer NX22354. Sample HGF 10 ng/mL Inhibitor Cells migrated 1 - 40 2 + 240 3 + mAba, 1 pg/mL 120 4 + NX22354, 1 uM 40 5 + NX22354,0.2 uM 25 6 + NX22354, 0.04 uM 200 aAnti-HGF antibody was MAB294 from R&D Systems, Inc. Table 7. Partially 2'-O-methyl substituted variants of NX22354. SEQUENCE SEQ. ID. No. NX22354 GGACGAUGCGGCGAGUGCCUGUUUAUGUCAUCGUCC 13 (parent) * ** * ** *** * * * * * * HGFOMel GGACGAUGCGGCGAGUGCCUGUUUAUGUCAUCGUCCg 156 HGFOMe2 GGACGAUGCGGCGAGUGCCUGUUUAUGUCAUCGUCCg 157 HGFOMe3 GGACGAUGCGGCGAGUGCCUGUUUAUGUCAUCGUCCg 158 HGFOMe4 GGACGAUGCGGCGAGUGCCUGUUUAUGUCAUCGUCCg 159 Parent 36mer sequence of NX22354 (purines marked with asterisks). The substituted positions are indicated by underlines. The OMel sequence has five substitutions while the others have four. For technical reasons, a G residue was added at the 3'-end of each aptamer. Table 8. Binding and Dissociation Constants SELEX Round Protein Kd random IgG, ~1 PM 7c IgG, 23 nM random c-met 100 nM 7c c-met 2 nM WO 01/09159 PCT/USOO/20139 65 Table 9. 40N7 sequences isolated from a plate SELEX on human c-met. Clone name: (number of isolates). Sequence SEQ ID NO: FAMILY 1: 7C -1: (2) UUUGACUAUGUCUGACGGGUCUGUGGUCAAUUCCGCCCC 160 FAMILY 2 7C -4: (1) AUCCGUGUUGAUGUCCAUAUAACCUUAUCCCGUCGCUCCC 161 7C -5: (1) GUGUUGACUUCUAGCCAGAAUAACAUUUUGUACCCCUCCC 162 FAMILY 3 7C -2: (1) UCGUUGAGCUUUUGAUAGGGCUUGUUCUUCGAGCGUCCC 163 7C-23: (1) UGAUCUUGGGUUUGAUCGUAAUUACUUCACCCUCCGUCCC 164 FAMILY 4 7C-26: (2) CUCCUUUUCCGCUAAACAAGACCACUUUGAGCCCUGCCCC 165 FAMILY 5 7C-25: (1) CCACCUCGUUACGUACUGAUUUUGGCAUCGCAGUUUGCCC 166 7C-27: (1) GGGCACCUCGAUACGUACUGAUUUUGAAUAUCAGUUAGCCCC 167 OTHERS 7C-21: (1) CGAUUCGUCGUAUAGAAAUGAUUUGAAUGCACCUCCUCCC 168 7C-24: (1) UGUGUUUGUGUGUUGUGUUUGUUAUUCCUGUUUGUGUCCU 169 7C-32: (1) UCGGUCGUAAAAAAUCGUUGGUGUCUAUCUAUUGUUCUCCC 170 Presumed IgG 1 aptamers 7C -3: (1) UGCUCCAGAGGAACCAUCGUUUACUUCAUUUAUUCGCCC 171 7C-22: (1) UGCUCCUUAGGAACCAUCGUCUAUAUCCCAUUCUGACUGCC 172 7C- 30: (1) UGCUCCUCAGGAACCAUCGUUUUUCCCAUGUCCUUCUGCC 173 7C-29: (3) UGCUCCUUGGAUUACCAAGGAACCAUUUUCCUCUACCCCC 174 aN7 fixed sequences are not shown. (5'-GGGAGGACGAUGCGG-N CAGACGACUCGCCCGA-3') WO 01/09159 PCT/USOO/20139 66 Table 10. 30N8 sequences isolated from a plate SELEX on human c-met. Clone name: (number of isolates). Sequencea SEQ ID NO: FAMILY 1: 7b-1: (4) GUGCUCAUUACGAACUUGACCGAUGCCUA 175 7b-9: (1) GGUGCUCAUUACGAACUUGACCGAAGCCUA 176 7b-18: (1) GGUGCUCAUUACGAACUUGACCGAUGCCUA 177 7b-3: (1) AGUGCUCCAAUGAACUUUGCUCGCUGA 178 7b-8: (1) GGUGCUCCGUUUGGAACUUGAUCGGUAGGA 179 7b-7: (1) GUGCUCAUUCAGAACUUGACGUAUAACCA 180 7b-14 (1) GGUGCUCCUUAGGAACUUGACCGUCCGCCA 181 7b-16: (1) GUGGUGCUCCACUAACCAAGUGGAACCUUG 182 consensus: GUGCUC-UU- -GAACUUGACCG 183 OTHERS: 7b -10: (1) ACGAUAAGUGGGAGUGAGUAAGUUUGAGUA 184 7b-12: (1) CCUAGACCCCCAGGUUCCUCCCCACUAGUC 185 aN8 fixed sequences are not shown. (5'-GGGAGAUAAGAAUAAACGCUCAA-N UUCGACAGGAGGCUCACAACAGGC-3') WO 01/09159 PCT/USOO/20139 67 Table 11. ac3 Family 1 aptamer sequences. Clone Sequence of variable region Seq. KD SEQ name length (nM) ID (# of 5'-gggagacaagaauaaacgcucaa [40N] NO: isolates) uucgacaggaggcucacaacaggc-3' 310 7.3 (2) Uucuacgu uguuuaagggcuuauaugagcgcauuauaccc 40 22 194 7.6; uucaacgc uguuuaagggcuuauaugagcgcguuauaccc 40 ND 195 17.12A 7.12 Uucaacgc uguuuaagggcuuauaugagcgcguuacaccc 40 ND 196 7.24(5) Uucaacgc uguucaagggcuuauaugagcgcguuauaccc 40 170 197 7.25 Uucaacga uguuuaagggcuuauaugagcgcguuauaccc 40 ND 198 7.34 uucau gaa guccaagggcuuauaugagcgcguuauaccc 39 ND 199 7.36(3) Uucaacgc ugucaaagggcuuauaugagcgcguuauaccc 40 ND 200 7.37(2) uu aacgu uguucaaggguuuauaugagugcguuauaccc 39 ND 201 7.38(2) Uucaacgc uguccaagggcuuauaugagcgcguuauaccc 40 49 202 7.49 Uucaacggauguccaagggcuu uaugagcgcguuauaccc 40 ND 203 7.53 Uucgacgc uguucaagggcuuauaugagcgcauuauaucc 40 ND 204 7.54(2) Uucgacgc uguucaagggcuuauaugagcgcguuauaccc 40 230 205 7.57(2) Uucgacga uguccaagggcuuauaugagcgcauuauaccc 40 ND 206 7.63 Uucaacgc uguucaagggcuuauaugagcgcguuacaccc 40 ND 207 7.64 uuc auga uguucaagggcuuauaugagcgcauuauaccc 39 ND 208 7.77(2) Uucaacga uguugaggggcuuauaugagcgcauuauaccc 40 770 209 7.80 Uucaacga uguccaagggcuuauaugagcgcauuauaccc 40 ND 210 7.86 Uucaacgc uguucaagggcuuaugugagcgcguuauaccc 40 ND 211 7.91 Uucaacgu uguccaagggcuuauaugagcgcauuauaccc 40 ND 212 7.115 Uucaacgc uguucaagggcuuauaugagcgcauuauaccc 40 ND 213 7.121 Uucaacga uguccaagggcuuauaugagcggauua ccc 38 ND 214 7.124 Uucaacac ugu gaagggcuuauaugagcgcgucauaccc 39 ND 215 7.127 Uucaacgu uguucaagggcuuauaugagcgcguuauaccc 40 ND 216 15.2 Uucaacgu ugucaaagggcuuauaugagcggauua ccc 38 6 217 15.3 (3); Uucaacgu uguccaagggcuuauaugagcggauua ccc 38 8 218 17.17 15.7 Uucuacga ugucaaagggcuuauaugagcggauua ccc 38 5 219 15.8 Uucgacgc uguugaagggcuuauacgagcggauua ccc 38 5 220 15.10 Uucaacgc uguucaagggcuuauaugagcggauua ccc 38 20 221 15.14 Uucaacau uguccaagggcuuauaugagcggauua ccc 38 6 222 15.17 Uucaacgu ugucaaagggcuuauacgggcggauua ccc 38 4 223 WO 01/09159 PCT/USOO/20139 68 Table 11. (Cont.) Clone Sequence of variable region Seq. KD SEQ name length (nM) ID (# of 5'-gggagacaagaauaaacgcucaa [40N] NO: isolates) uucgacaggaggcucacaacaggc-3' 310 15.18 Uucaacgc ugug aagggcuuauaugagcggauua ccc 37 2 224 (2) 15.20 Uucaacgc uguccaagggcuuauaugagcgcauuauaccc 40 20 225 15.27 Uucgacua uguccaagggcuuauaugagcggauua ccc 38 ND 226 15.28 Uucgacga ugucuaagggcuuauaugagcggauua ccc 38 ND 227 15.40; Uucaacgc uguugaagggcuuauacgagcggauua ccc 38 ND 228 17.12B 15.41 Uucaacgu uguccaagggcuuauacgagcggauua ccc 38 ND 229 15.42; Uucaacgc uguccaagggcuuauacgagcggauua ccc 38 ND 230 17.14 (2) 15.46; Uucgacgc ugug aagggcuuauaugagcggauua ccc 37 40 231 17.20 15.47 Uucaacgu ugucaaagggcuuauacgagcggauua ccc 38 ND 232 15.48 Uucaacgc uguugaagggcuuauaugagcggauua ccc 38 ND 233 15.49 Uucuacgu ugucuaagggcuuauaugagcggauua ccc 38 ND 234 15.50; Uucgacgc ugug aagggcuuauacgagcggauua ccc 37 30 235 17.3 15.52 Uucaacgc uguucaagggcuuauacgagcggauua ccc 38 ND 236 15.53 Uucaacgc uguccuagggcuuauaugagcgcaggauaccc 40 70 237 15.55 Uucuacgc uguuuaagggcuuauaugagcgaauua ccc 38 ND 238 15.57 Uucuacgu uguccaagggcuuauaugagcggauua ccc 38 ND 239 15.58 Uucgacgu uguugaagggcuuauaugagcggauua ccc 38 ND 240 17.1 Uucaacgc ugucaaagggcuuauauaagcggauua ccc 38 380 241 17.2(2) Uucuacgc ugug aagggcuuauaugagcggauua ccc 37 2 242 17.5 Uucgacgc ugug aagggcuuauaugagcggau acaccc 38 5 243 17.7(2) Uucuacgc ugug aagggcuuauacgagcggauua ccc 37 6 244 17.8 Uucaacgu ugucuaagggcuuauaugagcggauua ccc 38 18 245 17.10 Uucuacgu uguugaagggcuuauaugagcggauua ccc 38 ND 246 17.11 Uucuacgc ugug aagggcuuauaugagcgaauua ccc 37 4 247 17.13 Uucaacgc uguccaagggcuuauaugggcggauua ccc 38 10 248 17.16 Uucaacgc ugug aagggcuuauacgagcggauua ccc 37 8 249 WO 01/09159 PCT/USOO/20139 69 Table 12. a0 3 Family 2 aptamer sequences Clone Sequence of variable region Seq. KD SEQ name length (nM) ID (# of NO: isolates) 5'-gggagacaagaauaaacgcucaa [40N] 310 uucgacaggaggcucacaacag gc-3' 7.4 GUACCGGAUCGCCCUGCCACGGUAUUUGAGACAUUGAAA 39 ND 250 7.5 (3) GGUAGUAAAUGGACUCCUGCCAUCCAAUACUAUCUCUGAG 40 >1000 251 7.13 UGUAGUCGCAUGUCGAGCAGCAAUUCCUGCCAUUGUAGG 39 >1000 252 7.14(2) UGAAGAACUAGACCUGCCCAAGUCCUUCAUCGUGCUUGCU 40 ND 253 7.27 (2) CGAUUAUACUAUCCCUGCCAGUAGUAAUCAGUGCUAUA 38 ND 254 7.29 CGGUGAAGACCUCUAUUAACAACAUGACCUGCCUGCGUUG 40 ND 255 7.32 CGCAAAUAUGUUCCUGCCAAAUACGGGCGUUGACGCUAGA 40 ND 256 7.43 GGACCCUGCCGAGCACAUUUAUUCUGGUAACUGAGCCCCC 40 ND 257 7.51 CGCUGAGAGAAAGCCCUGCCCUUUCAGCUCGAGAGUUAUA 40 ND 258 7.58 UGAGAUGCAGUUCCUGCCUGCUGCAUUUCUUAGAGUGUGU 40 ND 259 7.83 GAUUAACGGUUAUCCUGCCAACCGAUUAUAAGAGCAUGGA 40 ND 260 7.89 UGAGAGACUACAAUAGAACUUAUGUAACCUGCCACAUAGG 40 ND 261 7.97 UAGGAAGUGUAACCUGCCUCACGGUCCUAUCGAGUAGUUU 40 ND 262 7.100 UGAAAACGCAACCUGCCGGCGUCGUCCUUUGGGUAAUUUA 40 ND 263 7.104 AUAGGGGGUUACCUGCCGACCCCAGAAAUAAGCGUGAUU 39 ND 264 7.105 UCCUGCCAUAGCGUCUUCAUGUCUGACGUUUGAGUUUCCG 40 ND 265 7.107 UCCUAGGUUGGUCCUGCCACAGCUCAAAGGUUUAGCUUCA 40 ND 266 7.109 ACAUGCAGACAACCCUGCCUUCUGCGUGGUUUAGGAGUA 39 ND 267 7.120 AACCUCAGGCGACCUGCCGCUGUCUGAAGUUCGAGCAUAA 40 ND 268 7.122 ACUCAAGACCCUGCCACUAUGUGUUACUGAGUAGGAGCGU 40 ND 269 7.125 AUUCGAAAUACGGGUUAAAUCCCUGCCUUUAACACGACA 39 ND 270 15.19 UGUAGCCGCAUGUCGAGCAGCAAUUCCUGCCAUUGUAGG 39 770 271 15.21 CGGUGAAGACCUCUAUUAACAACAUGACCUGCCUGCGUUG 40 200 272 15.34 UCCCACCCUGCCUUGUCUGUUUGAUAGAGACACUGUCCUU 40 190 273 WO 01/09159 PCT/USOO/20139 70 Table 13. a3 3 orphan aptamer sequences Clone Sequence of variable region Seq. KD SEQ name 5'-gggagacaagaauaaacgcucaa [40N] length (nM) ID (# of uucgacaggaggcucacaacaggc-3' NO: isolates) 310 7.1 gguuugaaagauugccuguagcuccaaaucuuggugagcu 40 ND 274 7.2 ucccgccgauagcuuccacgaagaguuaucuguaaaacaa 40 ND 275 7.11 ugagcuccugauuccaaaccuauuccguuucugggu 36 ND 276 7.30 acuggacaagucaaucucuccggcuugagacuugguuuac 40 ND 277 7.33 (2) cgagcucuugcuuccaaaccuauuccagacguuu cuggg 40 ND 278 7.41 (2) gcgagccuauugucuaagaugcaccaggccuguuaagcau 40 >1000 279 7.42 gccuguacggcgauuaugucuuuaccuuaacuguucc 37 ND 280 7.46 uaccaauggcacgaauaacugacuaccccccaaaauggaa 40 ND 281 7.47 gcggggcuuugcucaaguguuugcaaacgguaaauuccac 40 ND 282 7.61 ccuaccgacguccgccgcuggguuaaccuguaaagucacu 40 ND 283 7.66(2) gugaaccgauaagcgaaaguaguaccccugcuugacuacu 40 >1000 284 7.67 ggagcuccuaguuccaaaccuauuccagaaguuuucugggu 41 ND 285 7.75 uaguacgcagucauagcggggcagggacuuucuccgugca 40 ND 286 7.76 uuauacugguaugccgccgaccagaauuaauccaaugcgu 40 ND 287 7.82 ugagcuccugguuccaaaccuauuccagacguuucagggu 40 ND 288 7.85 ucuggccugugacuguagucguuucuucgaguugugacgc 40 ND 289 7.92 cucaacgauguccaagggcuuauaugagcgcguuacccc 39 ND 290 7.93 gcgagccuauugucuaagaugcgccaagccuguaaagcau 40 ND 291 7.94 gacuagccggccugagauccuuguucgccacacaugcugg 40 ND 292 7.96 cuucccccgcaaacacauguuuaguacugggagacuuggg 40 ND 293 7.101 ugagcuccugauuccgaaccuauuccagacguuucugggu 40 ND 294 7.102 cugauccucuugucauuguacaucucgcag 30 ND 295 7.106 uacuaagccuaacaaaagagcggauauuggcgcggcacg 39 ND 296 7.108 agucuuaguaguaccgccugcuucuaaccuugggcgcuuu 40 ND 297 7.112 ugauuucaugacuuaugccgccggcaugacuucaaugacg 40 ND 298 7.114 ucaaaggacggaagugccugugcccgacuaaagaguugag 40 ND 299 7.118 Cuaucgaucguuuuuucauuucccccugaccaucgccug 39 ND 300 7.123 Uugucccgcgcagaaacgugacaaauuuaacacgcaccgu 40 ND 301 7.128 Uucaacguuguucaagggcuuauaugagcgcguuauaccc 40 ND 302 15.4(4) Ugauuucaugacuuaugccgccggcaugacuucaaugacg 40 2000 303 15.5 Gcauucaaaauuugcgagaacgaauagaaguccgagagcc 40 4000 304 15.13 Gcgggauuuuccugaucaucccacugauucggggccuuac 40 790 305 (2) 15.39 Ucaaucucggacuagacuaacgaccuugguugacgcuca 39 410 306 15.43 Cgccguuaucacgacgugcguucugggcgguacucgcgca 40 45 307

Claims (73)

1. A nucleic acid ligand to hepatocyte growth factor/scatter factor (HGF) identified according to the method comprising: a) preparing a candidate mixture of nucleic acids; 5 b) contacting the candidate mixture of nucleic acids with HGF, wherein nucleic acids having an increased affinity to HGF relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and 10 d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to HGF, whereby a nucleic acid ligand of HGF may be identified.

2. A purified and isolated non-naturally occurring nucleic acid ligand to HGF.

3. A purified and non-naturally occurring RNA ligand to HGF wherein said ligand 15 is selected from the group consisting of SEQ ID NOS:12-14 in Figure 7, SEQ ID NOS:15 17 in Figure 8, SEQ ID NOS:18-93 in Table 2, SEQ ID NOS:94-131 in Table 3, SEQ ID NOS:132-155 in Table 5, and SEQ ID NOS:156-159 in Table 7.

4. The nucleic acid ligand of claim 1 wherein HGF is associated with a solid support, and wherein steps b)-c) take place on the surface of said solid support. 20

5. The nucleic acid ligand of claim 4 wherein said solid support is comprised of nitrocellulose.

6. The nucleic acid ligand of claim 1 wherein said candidate mixture of nucleic acids is comprised of single stranded nucleic acids.

7. The nucleic acid ligand of claim 6 wherein said single stranded nucleic acids are 25 ribonucleic acids.

8. The nucleic acid ligand of claim 6 wherein said single stranded nucleic acids are deoxyribonucleic acids.

9. The nucleic acid ligand of claim 7 wherein said candidate mixture of nucleic acids comprises 2'-F (2'-fluoro) modified ribonucleic acids. 30

10. The purified and isolated non-naturally occurring nucleic acid ligand of claim 2 wherein said nucleic acid ligand is single stranded. WO 01/09159 PCT/USOO/20139 72

11. The purified and isolated non-naturally occurring nucleic acid ligand of claim 10 wherein said nucleic acid ligand is RNA.

12. The purified and isolated non-naturally occurring RNA ligand of claim 11 wherein said ligand is comprised of 2'-fluoro (2'-F) modified nucleotides. 5

13. A method for the isolation of nucleic acid ligands to HGF, comprising: a) preparing a candidate mixture of nucleic acids; b) contacting the candidate mixture of nucleic acids with HGF, wherein nucleic acids having an increased affinity to HGF relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; 10 c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to HGF, whereby a nucleic acid ligand of HGF may be identified. 15

14. The method of claim 13 wherein said candidate mixture comprises single stranded nucleic acids.

15. The method of claim 14 wherein said single-stranded nucleic acids comprise ribonucleic acids.

16. A method for the treatment of a tumor comprising administering a biologically 20 effective dose of a nucleic acid ligand to HGF.

17. A method for determining the level of HGF in an individual comprising: a) providing a nucleic acid ligand to HGF; b) contacting a biological fluid from said individual with said nucleic acid ligand; and 25 c) determining the amount of HGF that has bound to said nucleic acid ligand.

18. A method for inhibiting angiogenesis, the method comprising administering a biologically-effective dose of a nucleic acid ligand to HGF.

19. A pharmaceutical composition for the treatment of a tumor comprising a nucleic acid ligand to HGF and a pharmaceutically acceptable excipient. 30

20. A nucleic acid ligand to c-met identified according to the method comprising: a) preparing a candidate mixture of nucleic acids; WO 01/09159 PCT/USOO/20139 73 b) contacting the candidate mixture of nucleic acids with c-met, wherein nucleic acids having an increased affinity to c-met relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; c) partitioning the increased affinity nucleic acids from the remainder of the 5 candidate mixture; and d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to c met, whereby a nucleic acid ligand of c-met may be identified.

21. A purified and isolated non-naturally occurring nucleic acid ligand to c-met. 10

22. A purified and non-naturally occurring RNA ligand to HGF wherein said ligand is selected from the group consisting of SEQ ID NOS:160-174 in Table 9 and SEQ ID NOS:175-185 in Table 10.

23. The nucleic acid ligand of claim 20 wherein c-met is associated with a solid support, and wherein steps b)-c) take place on the surface of said solid support. 15

24. The nucleic acid ligand of claim 23 wherein said solid support is comprised of nitrocellulose.

25. The nucleic acid ligand of claim 20 wherein said candidate mixture of nucleic acids is comprised of single stranded nucleic acids.

26. The nucleic acid ligand of claim 25 wherein said single stranded nucleic acids 20 are ribonucleic acids.

27. The nucleic acid ligand of claim 25 wherein said single stranded nucleic acids are deoxyribonucleic acids.

28. The nucleic acid ligand of claim 26 wherein said candidate mixture of nucleic acids comprises 2'-F (2'-fluoro) modified ribonucleic acids. 25

29. The purified and isolated non-naturally occurring nucleic acid ligand of claim 21 wherein said nucleic acid ligand is single stranded.

30. The purified and isolated non-naturally occurring nucleic acid ligand of claim 29 wherein said nucleic acid ligand is RNA.

31. The purified and isolated non-naturally occurring RNA ligand of claim 30 30 wherein said ligand is comprised of 2'-fluoro (2'-F) modified nucleotides.

32. A method for the isolation of nucleic acid ligands to c-met, comprising: WO 01/09159 PCT/USOO/20139 74 a) preparing a candidate mixture of nucleic acids; b) contacting the candidate mixture of nucleic acids with c-met, wherein nucleic acids having an increased affinity to c-met relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; 5 c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to c met, whereby a nucleic acid ligand of c-met may be identified. 10

33. The method of claim 32 wherein said candidate mixture comprises single stranded nucleic acids.

34. The method of claim 33 wherein said single-stranded nucleic acids comprise ribonucleic acids.

35. A method for the treatment of a tumor comprising administering a biologically 15 effective dose of a nucleic acid ligand to c-met.

36. A method for inhibiting angiogenesis, the method comprising administering a biologically-effective dose of a nucleic acid ligand to c-met.

37. A pharmaceutical composition for the treatment of a tumor comprising a nucleic acid ligand to c-met and a pharmaceutically acceptable excipient. 20

38. A method for treating a disease in which elevated HGF is a causative factor, the method comprising administering a biologically-effective dose of a nucleic acid ligand to HGF.

39. A method for inhibiting tumor development, the method comprising administering a biologically effective dose of a nucleic acid ligand to HGF in combination 25 with a biologically effective dose of a nucleic acid ligand to vascular endothelial growth factor (VEGF).

40. A method for inhibiting tumor development, the method comprising administering a biologically effective dose of a nucleic acid ligand to HGF in combination with a biologically effective dose of a nucleic acid ligand to basic fibroblast growth factor 30 (bFGF). WO 01/09159 PCT/USOO/20139 75

41. A method for inhibiting tumor development, the method comprising administering a biologically effective dose of a nucleic acid ligand to HGF in combination with a biologically effective dose of a nucleic acid ligand to vascular endothelial growth factor (VEGF) and a biologically effective dose of a nucleic acid ligand to basic fibroblast 5 growth factor (bFGF).

42. A method for inhibiting tumor development, the method comprising administering biologically effective doses of nucleic acid ligands to at least two growth factors.

43. The method of claim 42 wherein said growth factors are selected from the group 10 consisting of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), transforming growth factor beta (TGFp), HGF, and keratinocyte growth factor (KGF).

44. A method for inhibiting tumor development, the method comprising administering biologically effective doses of nucleic acid ligands to at least two receptors 15 of growth factors.

45. The method of claim 44 wherein said growth factors are selected from the group consisting of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), transforming growth factor beta (TGF p), HGF, and keratinocyte growth factor (KGF). 20

46. A method of inhibiting tumor development, the method comprising administering biologically-effective doses of nucleic acid ligands to one or more receptors of growth factors in combination with biologically-effective doses of nucleic acid ligands to one or more growth factors.

47. The method of claim 46 wherein said growth factors are selected from the group 25 consisting of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), transforming growth factor beta (TGF p), HGF, and keratinocyte growth factor (KGF).

48. A nucleic acid ligand to an integrin identified according to the method comprising: 30 a) preparing a candidate mixture of nucleic acids; WO 01/09159 PCT/USOO/20139 76 b) contacting the candidate mixture of nucleic acids with said integrin, wherein nucleic acids having an increased affinity to said integrin relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; c) partitioning the increased affinity nucleic acids from the remainder of the 5 candidate mixture; and d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to said integrin, whereby a nucleic acid ligand of said integrin may be identified.

49. The nucleic acid ligand of claim 48 wherein said integrin is a 3 3 integrin. 10

50. The nucleic acid ligand of claim 49 wherein said p3 integrin is selected from the group consisting of am,3 integrin and avt3 integrin.

51. A purified and isolated non-naturally occurring nucleic acid ligand to an integrin.

52. A purified and non-naturally occurring RNA ligand to an integrin wherein said 15 ligand is selected from the group consisting of SEQ ID NO: 194-307.

53. The nucleic acid ligand of claim 48 wherein said integrin is associated with a solid support, and wherein steps b)-c) take place on the surface of said solid support.

54. The nucleic acid ligand of claim 53 wherein said solid support is a bead

55. The nucleic acid ligand of claim 48 wherein said candidate mixture of nucleic 20 acids is comprised of single stranded nucleic acids.

56. The nucleic acid ligand of claim 55 wherein said single stranded nucleic acids are ribonucleic acids.

57. The nucleic acid ligand of claim 55 wherein said single stranded nucleic acids are deoxyribonucleic acids. 25

58. The nucleic acid ligand of claim 56 wherein said candidate mixture of nucleic acids comprises 2'-F (2'-fluoro) modified ribonucleic acids.

59. The purified and isolated non-naturally occurring nucleic acid ligand of claim 51 wherein said nucleic acid ligand is single stranded.

60. The purified and isolated non-naturally occurring nucleic acid ligand of claim 30 59 wherein said nucleic acid ligand is RNA. WO 01/09159 PCT/USOO/20139 77

61. The purified and isolated non-naturally occurring RNA ligand of claim 60 wherein said ligand is comprised of 2'-fluoro (2'-F) modified nucleotides.

62. A method for the isolation of nucleic acid ligands to an integrin, comprising: a) preparing a candidate mixture of nucleic acids; 5 b) contacting the candidate mixture of nucleic acids with said integrin, wherein nucleic acids having an increased affinity to said integrin relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and 10 d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to said integrin, whereby a nucleic acid ligand of said integrin may be identified.

63. The method of claim 62 wherein said candidate mixture comprises single stranded nucleic acids. 15

64. The method of claim 63 wherein said single-stranded nucleic acids comprise ribonucleic acids.

65. The method of claim 62 wherein said integrin is a 13 integrin.

66. The method of claim 65 wherein said P3 integrin is X0i 3 integrin.

67. A method for the treatment of a disease resulting from platelet activation, the 20 method comprising administering a biologically-effective amount of a nucleic acid ligand to a S3 integrin.

68. A method for treating deep vein thrombosis comprising administering a biologically-effective amount of a nucleic acid ligand to a p3 integrin.

69. A pharmaceutical composition for the treatment of deep vein thrombosis 25 comprising a nucleic acid ligand to a S3 integrin and a pharmaceutically acceptable excipient.

70. A method for detecting a deep vein thrombosis in an individual, the method comprising: (a) providing a nucleic acid ligand to a p3 integrin, said nucleic acid ligand 30 conjugated to a radioactive label; (b) administering said nucleic acid ligand to said individual; and WO 01/09159 PCT/USOO/20139 78 (c) detecting the site of said thrombosis by analyzing the localization of said nucleic acid ligand using a radioimaging technique.

71. An anti-clotting composition for use in acute coronary syndromes and percutaneous coronary intervention, the composition comprising a nucleic acid ligand to a 5 [3 integrin and a pharmaceutically-acceptable excipient.

72. A method for the treatment of a disease in which o'I 3 activation is a contributing pathogenic factor, the method comprising administering a biologically effective dose of a nucleic acid ligand to c A and a pharmaceutically acceptable excipient.

73. The method of claim 72 wherein said disease is selected from the group 10 consisting of cancer, diabetic retinopathy, retinopathy of prematurity, macular degeneration, endometriosis, psoriasis, rheumatoid arthritis, stroke, osteoporosis, and restenosis.